Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Staphylococcus Aureus Infection

  • Author: Elizabeth P Baorto, MD, MPH; Chief Editor: Russell W Steele, MD  more...
 
Updated: Jun 30, 2016
 

Practice Essentials

Both community-associated and hospital-acquired infections with Staphylococcus aureus have increased in the past 20 years, and the rise in incidence has been accompanied by a rise in antibiotic-resistant strains—in particular, methicillin-resistant S aureus (MRSA) and, more recently, vancomycin-resistant strains.

An example of radiographic findings in S aureus infections is shown in the image below.

Posteroanterior chest radiograph of a 15-year-old Posteroanterior chest radiograph of a 15-year-old with staphylococcal endocarditis and multiple septic emboli, revealing borderline cardiomegaly, multiple nodular infiltrates, and bilateral pleural effusions.

Signs and symptoms

Types and presentation of S aureus infection include the following:

  • Skin and soft tissue (impetigo): A small area of erythema that progresses into bullae (filled with cloudy fluid) that rupture and heal with the formation of a honey-colored crust
  • Scalded skin syndrome (Ritter disease): A relatively rare, toxin-mediated disorder with superficial fragile blisters that burst, leaving a tender base; often accompanied by fever and occasionally by mucopurulent eye discharge
  • Folliculitis: A tender pustule that involves the hair follicle
  • Furuncle: Small abscesses characterized by exuding purulent material from a single opening; involves both the skin and the subcutaneous tissues in areas with hair follicles
  • Carbuncle: An aggregate of connected furuncles, with several pustular openings
  • Bone infections (osteomyelitis): In children, sudden onset of fever and bony tenderness or a limp; pain may be throbbing and severe; however, presentation in neonates can be subtle
  • Septic arthritis: Decreased range of motion, warmth, erythema, and tenderness of the joint with constitutional symptoms and fever; however, these signs may be absent in infants (in whom the hip is the most commonly involved joint)
  • Endocarditis: Initially presents as fever and malaise; peripheral emboli may be present; may involve healthy valves
  • Toxic shock syndrome: Fever, diffuse macular erythema, and hypotension, with involvement of 3 or more organ systems; can be rapidly progressive in previously healthy individuals
  • Pneumonia: Most common in infants, young children, and debilitated patients; a short prodrome of fever followed by rapid onset of respiratory distress; prominent GI symptoms may also occur
  • Thrombophlebitis: Fever, pain, and occasionally erythema at the insertion site of an intravenous catheter; usually affects hospitalized patients
  • Deep tissue abscess and infection: Muscles[1, 2, 3, 4] and organs can become infected, including the parotid gland, eyes, liver, spleen, kidneys, and central nervous system[5] ; deep abscesses also may occur[6] ; fever with or without localizing pain is typical

See Clinical Presentation for more detail.

Diagnosis

Folliculitis, furuncle, and carbuncle

  • Diagnosis based on clinical appearance
  • Aspiration or incision and culture of purulent material from the lesion occasionally diagnostic

Osteomyelitis

  • Cultures of bone aspirate
  • Blood culture results positive in only 30-50% of pediatric patients
  • C-reactive protein levels and erythrocyte sedimentation rate are generally elevated in acute disease
  • Bone scan with increased technetium-99m–labeled diphosphonate uptake supports the clinical diagnosis; however, this modality is not as useful in neonates or after trauma or surgery
  • MRI is the best imaging modality for defining purulent collections and for planning surgery
  • On plain film radiographs, destructive bone changes are usually observed 2 weeks after infection

Septic arthritis

  • Gram stain and culture of joint fluid is the primary means of diagnosis
  • Direct inoculation of synovial fluid into culture bottles may improve culture yield
  • Median white blood cell count in joint fluid is 60.5 × 109, with neutrophil predominance >75%
  • Synovial fluid glucose levels are often low
  • Plain radiographs show capsular swelling
  • MRI or CT scanning is the imaging method of choice for pyogenic sacroiliitis

Endocarditis

  • Blood culture is the most important diagnostic procedure
  • Inject the blood sample into hypertonic media if the patient has been exposed to antibiotics
  • Obtain 3-5 sets of large-volume blood cultures within the first 24 hours
  • Echocardiography is a valuable adjunct

Pneumonia

  • Blood cultures are more likely to be positive in secondary than primary disease (90% vs 20%)
  • An adequate respiratory tract specimen should be obtained prior to initiating therapy; specimens may include endotracheal sampling, pleural fluid, or lung tap
  • Sputum specimens are inadequate because upper respiratory tract colonization is common
  • No radiologic features are highly specific
  • Typical radiographic features are unilateral consolidation in primary staphylococcal pneumonia and bilateral infiltrates in secondary cases
  • Early in the disease course, the chest radiograph may reveal minimal infiltrates, but within hours, infiltrates progress rapidly
  • Pleural effusion, pneumatoceles, and pneumothorax are also common
  • In oncology patients, S aureus may cause pulmonary nodules[7]

Thrombophlebitis

  • Obtain a blood culture through the intravenous line and a peripheral blood culture

See Workup for more detail.

Management

Antibiotic regimens include the following:

  • Empiric therapy with penicillins or cephalosporins may be inadequate because of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)[8]
  • Combination therapy with a penicillinase-resistant penicillin or cephalosporin (in case the organism is methicillin-sensitive S aureus [MSSA])[9] and clindamycin or a quinolone
  • Clindamycin, trimethoprim-sulfamethoxazole (TMP-SMX), rifampin, doxycycline, or a quinolone
  • TMP-SMX and rifampin in combination, rather than singly
  • Clindamycin (rather than TMP-SMX) may become the preferred outpatient antibiotic therapy in regions with a relatively low incidence of clindamycin resistance[10]
  • The Infectious Diseases Society of America has published treatment guidelines for MRSA infection[11]

Treatment of specific infections

Impetigo, folliculitis, furuncle, carbuncle:

  • Superficial or localized skin infections: A topical agent such as mupirocin or retapamulin; however, most CA-MRSA strains are (or readily become) resistant to mupirocin
  • More extensive or serious skin disease and bullous impetigo: Oral antistaphylococcal agents[12]
  • Drainage of pus collections is of paramount importance[13]

Scalded skin syndrome (Ritter disease):

  • Eradication of the focal infection to end toxin production
  • Large doses of intravenous antistaphylococcal agents such as oxacillin or a first-generation cephalosporin such as cefazolin, combined with clindamycin

Osteomyelitis:

  • Empiric semisynthetic penicillin and clindamycin
  • In patients with allergy to penicillin, a first-generation cephalosporin and clindamycin
  • Vancomycin or linezolid when the other drugs mentioned are absolutely not tolerated or when resistance or the clinical course dictates
  • Minimum effective treatment time is 4-6 weeks; therapy can be completed orally[14]
  • Surgery to drain purulent material from the subperiosteal space or remove infected foreign material

Septic arthritis:

  • A parenteral antistaphylococcal drug (eg, oxacillin, which is penicillinase resistant; clindamycin; cefazolin)
  • Therapy usually continues for at least 4 weeks; duration of parenteral therapy is debated
  • Joint fluid that reaccumulates should be removed and a sample should be cultured
  • Hip or shoulder infections in infants require prompt drainage to prevent bony destruction
  • Surgical drainage is indicated if needle drainage is inadequate

Endocarditis:

  • The combination of a beta-lactam and an aminoglycoside (eg, nafcillin and gentamicin)
  • In patients with MRSA, combinations of vancomycin with aminoglycosides
  • Rifampin can be added to combination therapy, especially for prosthetic valve endocarditis
  • Duration of therapy is at least 4 weeks
  • Bacteremia, fever, and leukocytosis for at least a week after therapy is initiated

Toxic shock syndrome:

  • Surgical exploration and drainage of all potential foci of infection

Thrombophlebitis:

  • Removal of the infected intravenous line in patients who are immunocompromised or severely ill or when infection cannot be eradicated medically

Bacteremia :

  • Daptomycin, with or without beta-lactams, controls S aureus bacteremia without worsening renal dysfunction. In a cohort of patients with mild or moderate renal insufficiency, more than 80% responded to treatment, with no detrimental effect on their kidneys. Currently, the combination of daptomycin with beta-lactams is recommended only as salvage therapy for refractory MRSA bacteremia.[15]

See Treatment and Medication for more detail.

Next

Background

Bacteria of the genus Staphylococcus are gram-positive cocci that are microscopically observed as individual organisms, in pairs, and in irregular, grapelike clusters. The term Staphylococcus is derived from the Greek term staphyle, meaning "a bunch of grapes." Staphylococci are nonmotile, non–spore-forming, and catalase-positive bacteria. The cell wall contains peptidoglycan and teichoic acid. The organisms are resistant to temperatures as high as 50°C, to high salt concentrations, and to drying. Colonies are usually large (6-8 mm in diameter), smooth, and translucent. The colonies of most strains are pigmented, ranging from cream-yellow to orange.

The ability to clot plasma continues to be the most widely used and generally accepted criterion for the identification of Staphylococcus aureus. One such factor, bound coagulase, also known as clumping factor, reacts with fibrinogen to cause organisms to aggregate. Another factor, extracellular staphylocoagulase, reacts with prothrombin to form staphylothrombin, which can convert fibrinogen to fibrin. Approximately 97% of human S aureus isolates possess both of these forms of coagulase.

S aureus is ubiquitous and may be a part of human flora found in the axillae, the inguinal and perineal areas, and the anterior nares. von Eiff et al described 3 patterns of carriage: those who always carry a strain, those who carry the organism intermittently with changing strains, and a minority of people who never carry S aureus.[16] Persistent carriage is more common in children than in adults. Nasal carriers may be divided into persistent carriers with high risk of infection and intermittent or noncarriers with low risk of infection.[17]

Wenzel and Perl found that, among healthy adults, carrier rates of 11-32% were detected in the general population, and a prevalence of 25% was detected in hospital personnel.[18] Using pulsed-field gel electrophoresis (PFGE) for molecular typing, von Eiff et al found that, in most patients with S aureus bacteremia, the isolate from the patient's blood is identical to that found in the anterior nares.[16] Persistent nasal carriage depends on host genetic determinants.[19]

Curiously, community-associated methicillin-resistant S aureus (CA-MRSA) is less often found in the anterior nares than are methicillin-sensitive S aureus (MSSA) and hospital-acquired methicillin-resistant S aureus (HA-MRSA)[20, 21, 22, 23] ; rather, it colonizes the skin, particularly in the perineal area[24] and the rectum.[25] It also colonizes the pharynx,[26] gut,[27] and vagina.[28, 29] Another interesting finding is the protective effect of consumption of hot coffee or tea for nasal carriage of MRSA.[30] In contrast, hormonal contraceptive use is a significant risk factor for nasal carriage of S aureus.[31] [#IntroductionPathophysiology]

Previous
Next

Pathophysiology

The organism may cause disease through tissue invasion and toxin production.[32] The toxins liberated by the organism may have effects at sites distant from the focus of infection or colonization.

Tissue invasion

The postulated sequence of events that leads to infection is initiated with carriage of the organism. The organism is then disseminated via hand carriage to body sites where infection may occur (either through overt breaks in dermal surfaces, such as vascular catheterization or operative incisions, or through less evident breakdown in barrier function, such as eczema or shaving-associated microtrauma).

The hallmark of staphylococcal infection is the abscess, which consists of a fibrin wall surrounded by inflamed tissues enclosing a central core of pus containing organisms and leukocytes. From this focus of infection, the organisms may be disseminated hematogenously, even from the smallest abscess. The ability to elaborate proteolytic enzymes facilitates the process. This may result in pneumonia, bone and joint infection, and infection of the heart valves. In immunocompromised hosts (eg, patients with cancer who are neutropenic and have a central venous line), 20-30% develop serious complications or fatal sepsis following catheter-related S aureus bacteremia.

Persistent deep-seated infections have now been linked to small-colony variants of the organism.[33] This population is more resistant to antibiotics and grows slowly. These organisms have been described in patients with cystic fibrosis and may contribute to the persistence of S aureus in these patients.

Toxin-mediated disease

The organism also elaborates toxins that can cause specific diseases or syndromes and likely participate in the pathogenesis of staphylococcal infection.[34] Enterotoxin-producing strains of S aureus cause one of the most common food-borne illnesses. The most common presentation is acute onset of vomiting and watery diarrhea 2-6 hours after ingestion. The symptoms are usually self-limited. The cause is the proliferation of toxin-producing organisms in uncooked or partially cooked food that an individual carrying the staphylococci has contaminated.

A rare but well-described disorder in neonates and young children is staphylococcal scalded skin syndrome (Ritter disease). The organism produces an exfoliative toxin produced by strains belonging to phage group II. Initial features include fever, erythema, and blisters, which eventually rupture and leave a red base. Gentle shearing forces on intact skin cause the upper epidermis to slip at a plane of cleavage in the skin, which is known as the Nikolsky sign. How the exfoliative toxins produce epidermal splitting has not been fully elucidated.[35]

The most feared manifestation of S aureus toxin production is toxic shock syndrome (TSS). Although first described in children, it was most frequently associated with women using tampons during menstruation. Since the early 1990s, at least half of the cases have not been associated with menstruation. The syndrome is associated with strains that produce the exotoxin TSST-1, but strains that produce enterotoxins B and C may cause 50% of cases of nonmenstrual TSS. These toxins are superantigens, T-cell mitogens that bind directly to invariant regions of major histocompatibility complex class II molecules, causing an expansion of clonal T cells, followed by a massive release of cytokines. This cytokine release mediates the TSS; the resultant pathophysiology mimics that of endotoxic shock.

CA-MRSA

In a worldwide trend,[36] the proportion of infections caused by CA-MRSA has increased.[37] Initially noted in tertiary care centers, these infections are now increasingly common in the community.[38, 39] Resistance to methicillin confers resistance to all penicillinase-resistant penicillins and cephalosporins. This high level of resistance requires the mec gene that encodes penicillin-binding protein 2a. This protein has decreased binding affinity for most penicillins and cephalosporins. Methicillin resistance has a wide variety of phenotypic expression. Heterogeneous resistance, recognized in the first clinical isolates described, is the typical phenotype. In this case, all cells carry the genetic markers of resistance but only a small fraction of them express the phenotype. Homogenous resistance is less frequent, with a single population of cells that are inhibited only through high concentrations of antibiotics.

Methicillin-resistant S aureus (MRSA) was initially described in hospitalized populations.[40] University affiliation and greater number of beds were institutional risk factors. In pediatric centers, number of beds, region, and metropolitan population correlated with increased risk.

Since 1996, more patients with CA-MRSA have been described. The strains isolated from these patients are different from typical nosocomial organisms in their susceptibility patterns and in their PFGE characteristics. A clonal population, designated USA-300, has become the predominant circulating organism in most communities.[41, 42] Many of these strains produce the Panton-Valentine leukocidin, which is associated with a tendency to produce abscesses, invasiveness, thrombogenesis, and morbidity and mortality.[43, 44, 45, 46]

A 2012 report corroborates earlier reports which describe an increased prevalence of USA300 strains causing invasive infections.[47] High levels of antibody to the leukocidin are not protective,[48] however, so the role of this and other virulence factors and immunomodulatory bacterial products remains under investigation.[49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65]

A dose-dependent increase in risk of infection due to CA-MRSA with exposure to antibiotics has been reported.[66]

More recently, S aureus that is intermediately resistant to vancomycin has been reported in 2 hospitalized patients, which suggests that full resistance to vancomycin may eventually emerge,[67] although that has not yet occurred in the pediatric population.[68] Although the possibility of interspecies transfer of vancomycin-resistance genes from vancomycin-resistant Enterococcus was originally considered as the cause of this phenomenon, none of the species isolated have carried vanA, vanB, vanC1, vanC2, or vanC3 genes. Of note, the clinical isolates with intermediate resistance to vancomycin were from patients who had undergone prolonged vancomycin therapy for MRSA. Morphologically, these isolates were found to have increased extracellular material associated with the cell wall that may have been selected for during a prolonged antibiotic course. Some virulence genes appear to be linked to decreased susceptibility to vancomycin.[69, 70]

Most recently, the emergence of newly described mec genes and chromosomal cassettes from bovine sources has been described.[71, 72] Thus, the issue of antimicrobial resistance in S aureus continues to evolve.[73]

Previous
Next

Frequency

United States

Numbers of both community-associated and hospital-acquired infections have increased in the past 20 years. From 1990-1992, data from the National Nosocomial Infections Surveillance System for the Centers for Disease Control and Prevention (CDC) revealed that S aureus was the most common cause of nosocomial pneumonia and operative wound infections and the second most common cause of nosocomial bloodstream infections.

A recent analysis of laboratory-confirmed MRSA cases in the Active Bacterial Core Surveillance database (which covers 9 geographic regions and represents some 4.4 million children younger than 18 years of age) indicates that community-acquired invasive MRSA infection is increasing among children, particularly among black children and infants younger than 90 days of age. The incidence of community-acquired MRSA increased from 1.1 case per 100,000 children in 2005 to 1.7 cases per 100,000 in 2010. The yearly increase in incidence, adjusted for race and age, was 10.2%. The adjusted incidence of invasive MRSA among black children was 6.7 cases per 100,000 in 2010, compared with 1.6 cases per 100,000 for children of other races.[74, 75]

An analysis of 148 consecutive patients with acute musculoskeletal S aureus infection (111 with MSSA and 37 with MRSA) found that the proportion of pediatric MRSA infections increased from 11.8% to 34.8% between 2001 and 2009, resulting in longer mean hospitalizations (13 vs 8 days).[76] . In addition, children with MRSA infection more often required surgical procedures (38% vs. 15%), experienced more infection-related complications (24% vs 6%), and were more often admitted to the intensive care unit (16% vs 3%).

Frequency of antibiotic resistance: In a disturbing trend, antibiotic resistance among these isolates has increased because of antibiotic pressure. Currently, less than 5% of clinical isolates remain sensitive to penicillin. Resistance to penicillin was reported as early as 1942 and is mediated by beta-lactamase, a serine protease that hydrolyzes the lactam ring. In the 1980s, MRSA emerged as a prominent hospital-based infection; consequently, the use of vancomycin increased. A CDC survey revealed that the proportion of methicillin-resistant isolates with sensitivity only to vancomycin increased from 22.8% in 1987 to 56.2% in 1997.[77] Scattered reports of vancomycin resistance have been noted.[78] Community-onset MRSA infections are increasingly common,[79, 80] although geographic variations persist.[81] Recent data suggest that the incidence of MRSA infection may have peaked.[82, 83]

A study by Sutter et al analyzed 41,745 S aureus isolates from 39,207 pediatric patients and found that like recent trends seen in adults, the proportion of pediatric S aureus infections secondary to methicillin-resistant S aureus appear to be decreasing, as is variability in US geographical resistance rates. The authors also added S aureus susceptibility to clindamycin declined from 90% to 83% over a 10-year period.[84]

A large population based case-control study by Smit et al indicated that diabetes patients are almost three times more likely to contract community-acquired Staphylococcus aureus bacteremia, with the risk escalating with worsening disease.[85, 86]

 

International

The USA300 lineage of community-associated MRSA has become widespread in Latin America.[87] Incidence of staphylococcal skin and complicated infections among children in the United Kingdom has increased over the past decade or so as well[88, 89] , although the incidence of community-associated MRSA blood stream infection in the United Kingdom is less than that seen in the United States.[90] Other strains of community-associated MRSA have been described in Canada,[91, 92, 93, 94] Australia, Asia,[95, 96] and elsewhere in Europe.[97, 98, 99, 100, 101, 102, 103, 104, 105]

Previous
Next

Mortality/Morbidity

Morbidity and mortality from S aureus infection widely varies depending on the clinical entity. Although mortality is low in children with scalded skin syndrome, most fatalities are associated with delay in diagnosis.

Sex

The male-to-female ratio of skeletal infections is 2:1, mostly because boys are more likely to experience traumatic events.

Previous
 
 
Contributor Information and Disclosures
Author

Elizabeth P Baorto, MD, MPH Director, Division of Pediatric Infectious Diseases, Atlantic Health System

Disclosure: Nothing to disclose.

Coauthor(s)

David Baorto, MD, PhD Medical Knowledge Engineer, Department of Medical Informatics, Columbia University Medical Center

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Larry I Lutwick, MD Professor of Medicine, State University of New York Downstate Medical School; Director, Infectious Diseases, Veterans Affairs New York Harbor Health Care System, Brooklyn Campus

Larry I Lutwick, MD is a member of the following medical societies: American College of Physicians, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Chief Editor

Russell W Steele, MD Clinical Professor, Tulane University School of Medicine; Staff Physician, Ochsner Clinic Foundation

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, Southern Medical Association

Disclosure: Nothing to disclose.

Additional Contributors

José Rafael Romero, MD Director of Pediatric Infectious Diseases Fellowship Program, Associate Professor, Department of Pediatrics, Combined Division of Pediatric Infectious Diseases, Creighton University/University of Nebraska Medical Center

José Rafael Romero, MD is a member of the following medical societies: American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, New York Academy of Sciences, Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

References
  1. Jamal N, Teach SJ. Necrotizing fasciitis. Pediatr Emerg Care. 2011 Dec. 27(12):1195-9; quiz 1200-2. [Medline].

  2. Jaramillo D. Infection: musculoskeletal. Pediatr Radiol. 2011 May. 41 Suppl 1:S127-34. [Medline].

  3. Chou H, Teo HE, Dubey N, Peh WC. Tropical pyomyositis and necrotizing fasciitis. Semin Musculoskelet Radiol. 2011 Nov. 15(5):489-505. [Medline].

  4. Lane JW, Tang J, Taggard D, Byun R. Successful use of daptomycin and linezolid, without surgical intervention, in the treatment of extensive epidural abscess and bacteremia due to methicillin-resistant Staphylococcus aureus (MRSA). Infect Dis Clin Pract. Sept 2011. 19(5):362-364.

  5. Abdel-Haq N, Quezada M, Asmar BI. Retropharyngeal Abscess in Children: The Rising Incidence of Methicillin-Resistant Staphylococcus aureus. Pediatr Infect Dis J. 2012 Jul. 31(7):696-9. [Medline].

  6. McNeil JC, Hulten KG, Kaplan SL, Mahoney DH, Mason EO. Staphylococcus aureus Infections in Pediatric Oncology Patients: High Rates of Antimicrobial Resistance, Antiseptic Tolerance and Complications. Pediatr Infect Dis J. 2012 Sep 11. [Medline].

  7. Elliott DJ, Zaoutis TE, Troxel AB, Loh A, Keren R. Empiric Antimicrobial Therapy for Pediatric Skin and Soft-Tissue Infections in the Era of Methicillin-Resistant Staphylococcus aureus. Pediatrics. 2009 Jun. 123(6):e959-66. [Medline].

  8. Lee S, Choe PG, Song KH, Park SW, Kim HB, Kim NJ, et al. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia?. Antimicrob Agents Chemother. 2011 Nov. 55(11):5122-6. [Medline]. [Full Text].

  9. Williams DJ, Cooper WO, Kaltenbach LA, Dudley JA, Kirschke DL, Jones TF, et al. Comparative Effectiveness of Antibiotic Treatment Strategies for Pediatric Skin and Soft-Tissue Infections. Pediatrics. 2011 Aug 15. [Medline].

  10. [Guideline] Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children. Clin Infect Dis. 2011 Feb 1. 52(3):e18-e55. [Medline].

  11. Kemper AR, Dolor RJ, Fowler VG Jr. Management of skin abscesses by primary care pediatricians. Clin Pediatr (Phila). 2011 Jun. 50(6):525-8. [Medline].

  12. Sreeramoju P, Porbandarwalla NS, Arango J, Latham K, Dent DL, Stewart RM, et al. Recurrent skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus requiring operative debridement. Am J Surg. 2011 Feb. 201(2):216-20. [Medline].

  13. Pääkkönen M, Kallio PE, Kallio MJ, Peltola H. Management of Osteoarticular Infections Caused by Staphylococcus aureus Is Similar to That of Other Etiologies: Analysis of 199 Staphylococcal Bone and Joint Infections. Pediatr Infect Dis J. 2012 May. 31(5):436-8. [Medline].

  14. Boggs W. Daptomycin Treats S. aureus Bacteremia Without Nephrotoxicity. Medscape Medical News. January 8, 2013. Available at http://www.medscape.com/viewarticle/777276. Accessed: January 15, 2013.

  15. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001 Jan 4. 344(1):11-6. [Medline].

  16. van Belkum A, Verkaik NJ, de Vogel CP, Boelens HA, Verveer J, Nouwen JL. Reclassification of Staphylococcus aureus Nasal Carriage Types. J Infect Dis. 2009 Jun 15. 199(12):1820-6. [Medline].

  17. Wenzel RP, Perl TM. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect. 1995 Sep. 31(1):13-24. [Medline].

  18. Ruimy R, Angebault C, Djossou F, et al. Are host genetics the predominant determinant of persistent nasal Staphylococcus aureus carriage in humans?. J Infect Dis. 2010 Sep 15. 202(6):924-34. [Medline].

  19. Chen CJ, Hsu KH, Lin TY, Hwang KP, Chen PY, Huang YC. Factors associated with nasal colonization of methicillin-resistant Staphylococcus aureus among healthy children in Taiwan. J Clin Microbiol. 2011 Jan. 49(1):131-7. [Medline]. [Full Text].

  20. Nerby JM, Gorwitz R, Lesher L, Juni B, Jawahir S, Lynfield R. Risk Factors for Household Transmission of Community-associated Methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J. 2011 Nov. 30(11):927-32. [Medline].

  21. Fritz SA, Krauss MJ, Epplin EK, Burnham CA, Garbutt J, Dunne WM, et al. The natural history of contemporary Staphylococcus aureus nasal colonization in community children. Pediatr Infect Dis J. 2011 Apr. 30(4):349-51. [Medline]. [Full Text].

  22. Gesualdo F, Bongiorno D, Rizzo C, Bella A, Menichella D, Stefani S, et al. MRSA Nasal Colonization in Children: Prevalence Meta-Analysis, Review of Risk Factors and Molecular Genetics. Pediatr Infect Dis J. 2013 Jan 21. [Medline].

  23. Peters PJ, Brooks JT, McAllister SK, Limbago V, Lowery HK, Fosheim G, et al. Methicillin-resistant Staphylococcus aureus colonization of the groin and risk for clinical infection among HIV-infected adults. Emerg Infect Dis. April 2013. 19(4):623-629.

  24. Faden H, Lesse AJ, Trask J, Hill JA, Hess DJ, Dryja D. Importance of Colonization Site in the Current Epidemic of Staphylococcal Skin Abscesses. Pediatrics. 2010 Feb 15. [Medline].

  25. Lee CJ, Sankaran S, Mukherjee DV, Apa ZL, Hafer CA, Wright L. Staphylococcus aureus oropharyngeal carriage in a prison population. Clin Infect Dis. 2011 Mar 15. 52(6):775-8. [Medline].

  26. Nowrouzian FL, Dauwalder O, Meugnier H, Bes M, Etienne J, Vandenesch F, et al. Adhesin and Superantigen Genes and the Capacity of Staphylococcus aureus to Colonize the Infantile Gut. J Infect Dis. 2011 Sep. 204(5):714-21. [Medline].

  27. Milstone AM, Song X, Coffin S, Elward A. Identification and eradication of methicillin-resistant Staphylococcus aureus colonization in the neonatal intensive care unit: results of a national survey. Infect Control Hosp Epidemiol. 2010 Jul. 31(7):766-8. [Medline]. [Full Text].

  28. Nakamura MM, McAdam AJ, Sandora TJ, Moreira KR, Lee GM. Higher prevalence of pharyngeal than nasal Staphylococcus aureus carriage in pediatric intensive care units. J Clin Microbiol. 2010 Aug. 48(8):2957-9. [Medline].

  29. Matheson EM, Mainous AG 3rd, Everett CJ, King DE. Tea and coffee consumption and MRSA nasal carriage. Ann Fam Med. 2011 Jul-Aug. 9(4):299-304. [Medline].

  30. Zanger P, Nurjadi D, Gaile M, Gabrysch S, Kremsner PG. Hormonal Contraceptive Use and Persistent Staphylococcus aureus Nasal Carriage. Clin Infect Dis. 2012 Dec. 55(12):1625-32. [Medline].

  31. Bartlett AH, Hulten KG. Staphylococcus aureus pathogenesis: secretion systems, adhesins, and invasins. Pediatr Infect Dis J. 2010 Sep. 29(9):860-1. [Medline].

  32. Tuchscherr L, Heitmann V, Hussain M, Viemann D, Roth J, von Eiff C, et al. Staphylococcus aureus small-colony variants are adapted phenotypes for intracellular persistence. J Infect Dis. 2010 Oct 1. 202(7):1031-40. [Medline].

  33. Verkaik NJ, Dauwalder O, Antri K, Boubekri I, de Vogel CP, Badiou C. Immunogenicity of toxins during Staphylococcus aureus infection. Clin Infect Dis. 2010 Jan 1. 50(1):61-8. [Medline].

  34. Aalfs AS, Oktarina DA, Diercks GF, Jonkman MF, Pas HH. Staphylococcal scalded skin syndrome: loss of desmoglein 1 in patient skin. Eur J Dermatol. 2010 Jul-Aug. 20(4):451-6. [Medline].

  35. Bassetti M, Nicco E, Mikulska M. Why is community-associated MRSA spreading across the world and how will it change clinical practice?. Int J Antimicrob Agents. 2009 Jul. 34 Suppl 1:S15-9. [Medline].

  36. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010 Jul. 23(3):616-87. [Medline].

  37. Pickett A, Wilkinson M, Menoch M, Snell J, Yniguez R, Bulloch B. Changing incidence of methicillin-resistant staphylococcus aureus skin abscesses in a pediatric emergency department. Pediatr Emerg Care. 2009 Dec. 25(12):831-4. [Medline].

  38. Kairam N, Silverman ME, Salo DF, Baorto E, Lee B, Amato CS. Cutaneous Methicillin-Resistant Staphylococcus aureus in a Suburban Community Hospital Pediatric Emergency Department. J Emerg Med. 2011 Nov. 41(5):460-5. [Medline].

  39. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008 Jun 1. 46 Suppl 5:S344-9. [Medline].

  40. Tenover FC, Goering RV. Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. J Antimicrob Chemother. 2009 Sep. 64(3):441-6. [Medline].

  41. Talan DA, Krishnadasan A, Gorwitz RJ, Fosheim GE, Limbago B, Albrecht V, et al. Comparison of Staphylococcus aureus From Skin and Soft-Tissue Infections in US Emergency Department Patients, 2004 and 2008. Clin Infect Dis. 2011 Jul. 53(2):144-149. [Medline].

  42. Long CB, Madan RP, Herold BC. Diagnosis and management of community-associated MRSA infections in children. Expert Rev Anti Infect Ther. 2010 Feb. 8(2):183-95. [Medline].

  43. Lowy FD. How Staphylococcus aureus adapts to its host. N Engl J Med. 2011 May 26. 364(21):1987-90. [Medline].

  44. Hay R, Noor NM. Panton-Valentine leucocidin and severe Staphylococcus aureus infections of the skin: sole culprit or does it have accomplices?. Curr Opin Infect Dis. 2011 Apr. 24(2):97-9. [Medline].

  45. Ritz N, Curtis N. The Role of Panton-Valentine Leukocidin in Staphylococcus aureus Musculoskeletal Infections in Children. Pediatr Infect Dis J. 2012 May. 31(5):514-8. [Medline].

  46. Mendes RE, Deshpande LM, Smyth DS, Shopsin B, Farrell DJ, Jones RN. Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumonia. J Clin Microbiol. 2012 Nov. 50(11):3694-702. [Medline]. [Full Text].

  47. Hermos CR, Yoong P, Pier GB. High levels of antibody to panton-valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infection. Clin Infect Dis. 2010 Nov 15. 51(10):1138-46. [Medline].

  48. Grundmeier M, Tuchscherr L, Bruck M, Viemann D, Roth J, Willscher E. Staphylococcal strains vary greatly in their ability to induce an inflammatory response in endothelial cells. J Infect Dis. 2010 Mar 15. 201(6):871-80. [Medline].

  49. Strandberg KL, Rotschafer JH, Vetter SM, Buonpane RA, Kranz DM, Schlievert PM. Staphylococcal superantigens cause lethal pulmonary disease in rabbits. J Infect Dis. 2010 Dec 1. 202(11):1690-7. [Medline].

  50. Li M, Cheung GY, Hu J, Wang D, Joo HS, Deleo FR, et al. Comparative analysis of virulence and toxin expression of global community-associated methicillin-resistant Staphylococcus aureus strains. J Infect Dis. 2010 Dec 15. 202(12):1866-76. [Medline].

  51. Torres VJ, Stauff DL, Pishchany G, Bezbradica JS, Gordy LE, Iturregui J, et al. A Staphylococcus aureus regulatory system that responds to host heme and modulates virulence. Cell Host Microbe. 2007 Apr 19. 1(2):109-19. [Medline]. [Full Text].

  52. Pishchany G, McCoy AL, Torres VJ, Krause JC, Crowe JE Jr, Fabry ME, et al. Specificity for human hemoglobin enhances Staphylococcus aureus infection. Cell Host Microbe. 2010 Dec 16. 8(6):544-50. [Medline]. [Full Text].

  53. Kobayashi SD, Malachowa N, Whitney AR, Braughton KR, Gardner DJ, Long D, et al. Comparative Analysis of USA300 Virulence Determinants in a Rabbit Model of Skin and Soft Tissue Infection. J Infect Dis. 2011 Sep. 204(6):937-41. [Medline]. [Full Text].

  54. Hota B, Lyles R, Rim J, Popovich KJ, Rice T, Aroutcheva A. Predictors of clinical virulence in community-onset methicillin-resistant Staphylococcus aureus infections: the importance of USA300 and pneumonia. Clin Infect Dis. 2011 Oct. 53(8):757-65. [Medline].

  55. Peyrani P, Allen M, Wiemken TL, Haque NZ, Zervos MJ, Ford KD, et al. Severity of disease and clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus strains not influenced by the presence of the Panton-Valentine Leukocidin gene. Clin Infect Dis. 2011 Oct. 53(8):766-71. [Medline].

  56. Kebaier C, Chamberland RR, Allen IC, Gao X, Broglie PM, Hall JD. Staphylococcus aureus a-Hemolysin Mediates Virulence in a Murine Model of Severe Pneumonia Through Activation of the NLRP3 Inflammasome. J Infect Dis. 2012 Mar. 205(5):807-17. [Medline].

  57. Rudkin JK, Edwards AM, Bowden MG, Brown EL, Pozzi C, Waters EM. Methicillin Resistance Reduces the Virulence of Healthcare-Associated Methicillin-Resistant Staphylococcus aureus by Interfering With the agr Quorum Sensing System. J Infect Dis. 2012 Mar. 205(5):798-806. [Medline].

  58. Sharma-Kuinkel BK, Ahn SH, Rude TH, Zhang Y, Tong SY, Ruffin F, et al. Presence of genes encoding panton-valentine leukocidin is not the primary determinant of outcome in patients with hospital-acquired pneumonia due to Staphylococcus aureus. J Clin Microbiol. 2012 Mar. 50(3):848-56. [Medline]. [Full Text].

  59. Soong G, Chun J, Parker D, Prince A. Staphylococcus aureus Activation of Caspase 1/Calpain Signaling Mediates Invasion Through Human Keratinocytes. J Infect Dis. 2012 May. 205(10):1571-9. [Medline].

  60. Otto M. How Staphylococcus aureus Breaches Our Skin to Cause Infection. J Infect Dis. 2012 May. 205(10):1483-5. [Medline].

  61. Wehrhahn MC, Robinson JO, Pascoe EM, Coombs GW, Pearson JC, O'Brien FG. Illness Severity in Community-Onset Invasive Staphylococcus aureus Infection and the Presence of Virulence Genes. J Infect Dis. 2012 Jun. 205(12):1840-8. [Medline].

  62. Garofalo A, Giai C, Lattar S, Gardella N, Mollerach M, Kahl BC. The Length of the Staphylococcus aureus Protein A Polymorphic Region Regulates Inflammation: Impact on Acute and Chronic Infection. J Infect Dis. 2012 Jul. 206(1):81-90. [Medline].

  63. Shallcross LJ, Fragaszy E, Johnson AM, Hayward AC. The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis. Lancet Infect Dis. 2013 Jan. 13(1):43-54. [Medline]. [Full Text].

  64. Suryadevara M, Clark AE, Wolk DM, Carman A, Rosenbaum PF. Molecular characterization of invasive Staphylococcus aureus infection in central New York children: importance of two clonal groups and inconsistent presence of selected virulence determinants. J Pediatr Infect Dis Soc. March 2013. 2(1):30-39.

  65. Schneider-Lindner V, Quach C, Hanley JA, Suissa S. Antibacterial Drugs and the Risk of Community-Associated Methicillin-Resistant Staphylococcus aureus in Children. Arch Pediatr Adolesc Med. 2011 Aug 1. [Medline].

  66. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med. 1999 Feb 18. 340(7):493-501. [Medline].

  67. Zheng X, Qi C, Arrieta M, O'Leary A, Wang D, Shulman ST. Lack of increase in vancomycin resistance of pediatric methicillin-resistant Staphylococcus aureus Isolates from 2000 to 2007. Pediatr Infect Dis J. 2010 Sep. 29(9):882-4. [Medline].

  68. Cameron DR, Ward DV, Kostoulias X, Howden BP, Moellering RC Jr, Eliopoulos GM. Serine/Threonine Phosphatase Stp1 Contributes to Reduced Susceptibility to Vancomycin and Virulence in Staphylococcus aureus. J Infect Dis. 2012 Jun. 205(11):1677-87. [Medline].

  69. Cheung A, Duclos B. Stp1 and Stk1: The Yin and Yang of Vancomycin Sensitivity and Virulence in Vancomycin-Intermediate Staphylococcus aureus Strains. J Infect Dis. 2012 Jun. 205(11):1625-7. [Medline].

  70. Shore AC, Deasy EC, Slickers P, et al. Detection of Staphylococcal Cassette Chromosome mec Type XI Encoding Highly Divergent mecA, mecI, mecR1, blaZ and ccr Genes in Human Clinical Clonal Complex 130 Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2011 Jun 2. [Medline].

  71. García-Álvarez L, Holden MT, Lindsay H, et al. Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study. Lancet Infect Dis. 2011 Jun 2. [Medline].

  72. Cameron DR, Howden BP, Peleg AY. The interface between antibiotic resistance and virulence in Staphylococcus aureus and its impact upon clinical outcomes. Clin Infect Dis. 2011 Sep. 53(6):576-82. [Medline].

  73. [Guideline] CDC. Interim guidelines for prevention and control of Staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep. 1997 Jul 11. 46(27):626-8, 635. [Medline].

  74. Iwamoto M, Mu Y, Lynfield R, Bulens SN, Nadle J, Aragon D, et al. Trends in Invasive Methicillin-Resistant Staphylococcus aureus Infections. Pediatrics. 2013 Oct. 132(4):e817-e824. [Medline].

  75. Laidman J. Community-Associated MRSA Incidence on the Rise in Children. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/811483. Accessed: September 30, 2013.

  76. Helwick C. MRSA Rising in Children With Musculoskeletal Infections. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/813484. Accessed: November 4, 2013.

  77. Saravolatz LD, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis. 2012 Aug. 55(4):582-6. [Medline].

  78. Frei CR, Makos BR, Daniels KR, Oramasionwu CU. Emergence of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections as a common cause of hospitalization in United States children. J Pediatr Surg. 2010 Oct. 45(10):1967-74. [Medline].

  79. Hadler JL, Petit S, Mandour M, Cartter ML. Trends in Invasive Infection with Methicillin-Resistant Staphylococcus aureus, Connecticut, USA, 2001-2010. Emerg Infect Dis. 2012 Jun. 18(6):917-24. [Medline]. [Full Text].

  80. Suryadevara M, Moro MR, Rosenbaum PF, Kiska D, Riddell S, Weiner LB. Incidence of invasive community-onset Staphylococcus aureus infections in children in Central New York. J Pediatr. 2010 Jan. 156(1):152-154.e1. [Medline].

  81. Landrum ML, Neumann C, Cook C, Chukwuma U, Ellis MW, Hospenthal DR. Epidemiology of Staphylococcus aureus Blood and Skin and Soft Tissue Infections in the US Military Health System, 2005-2010Staphylococcus aureus in US Military. JAMA. 2012 Jul 4. 308(1):50-9. [Medline].

  82. Hsiang MS, Shiau R, Nadle J, Chan L, Lee B, Chambers HF, et al. Epidemiologic similarities in pediatric community-associated methicillin-resistant and methicillin-sensitive Staphylococcus aureus in the San Francisco Bay area. J Pediatr Infect Dis Soc. September 2012. 1(3):200-211.

  83. Reyes J, Rincon S, Diaz L, et al. Dissemination of methicillin-resistant Staphylococcus aureus USA300 sequence type 8 lineage in Latin America. Clin Infect Dis. 2009 Dec 15. 49(12):1861-7. [Medline]. [Full Text].

  84. Sutter DE, Milburn E, Chukwuma U, Dzialowy N, Maranich AM, Hospenthal DR. Changing Susceptibility of Staphylococcus aureus in a US Pediatric Population. Pediatrics. 2016 Mar 1. [Medline].

  85. Smit J, Søgaard M, Schønheyder HC, Nielsen H, Frøslev T, Thomsen RW. Diabetes and risk of community-acquired Staphylococcus aureus bacteremia: A population-based case-control study. Eur J Endocrinol. 2016 Mar 10. [Medline].

  86. Davenport L. Diabetes Patients at Higher Risk of S aureus Blood Infection. Medscape Medical News. Available at http://www.medscape.com/viewarticle/860376. March 15, 2016; Accessed: April 27, 2016.

  87. Saxena S, Thompson P, Birger R, Bottle A, Spyridis N, Wong I. Increasing Skin Infections and Staphylococcus aureus Complications in Children, England, 1997-2006. Emerg Infect Dis. 2010 Mar. 16(3):530-533. [Medline].

  88. Otter JA, French GL. Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe. Lancet Infect Dis. 2010 Apr. 10(4):227-239. [Medline].

  89. Lessa FC, Mu Y, Davies J, Murray M, Lillie M, Pearson A. Comparison of incidence of bloodstream infection with methicillin-resistant Staphylococcus aureus between England and United States, 2006-2007. Clin Infect Dis. 2010 Oct 15. 51(8):925-8. [Medline].

  90. Golding GR, Levett PN, McDonald RR, Irvine J, Quinn B, Nsungu M. High rates of Staphylococcus aureus USA400 infection, Northern Canada. Emerg Infect Dis. 2011 Apr. 17(4):722-5. [Medline].

  91. Golding GR, Levett PN, McDonald RR, Irvine J, Nsungu M, Woods S, et al. A comparison of risk factors associated with community-associated methicillin-resistant and -susceptible Staphylococcus aureus infections in remote communities. Epidemiol Infect. 2010 May. 138(5):730-7. [Medline].

  92. Kim J, Ferrato C, Golding GR, Mulvey MR, Simmonds KA, Svenson LW, et al. Changing epidemiology of methicillin-resistant Staphylococcus aureus in Alberta, Canada: population-based surveillance, 2005-2008. Epidemiol Infect. 2010 Sep 21. 1-10. [Medline].

  93. Matlow A, Forgie S, Pelude L, Embree J, Gravel D, Langley JM, et al. National surveillance of methicillin-resistant Staphylococcus aureus among hospitalized pediatric patients in Canadian acute care facilities, 1995-2007. Pediatr Infect Dis J. 2012 Aug. 31(8):814-20. [Medline].

  94. Alesana-Slater J, Ritchie SR, Heffernan H, Camp T, Richardson A, Herbison P. Methicillin-resistant Staphylococcus aureus, Samoa, 2007-2008. Emerg Infect Dis. 2011 Jun. 17(6):1023-9. [Medline].

  95. Suzuki M, Yamada K, Nagao M, Aoki E, Matsumoto M, Hirayama T, et al. Antimicrobial Ointments and Methicillin-Resistant Staphylococcus aureus USA300. Emerg Infect Dis. 2011 Oct. 17(10):1917-20. [Medline].

  96. Tong SY, Bishop EJ, Lilliebridge RA, et al. Community-associated strains of methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus in indigenous Northern Australia: epidemiology and outcomes. J Infect Dis. 2009 May 15. 199(10):1461-70. [Medline].

  97. Salmenlinna S, Lyytikainen O, Vainio A, Myllyniemi AL, Raulo S, Kanerva M, et al. Human Cases of Methicillin-Resistant Staphylococcus aureus CC398, Finland. Emerg Infect Dis. 2010 Oct. 16(10):1626-9. [Medline].

  98. Tappe D, Schulze MH, Oesterlein A, Turnwald D, Müller A, Vogel U, et al. Panton-Valentine leukocidin-positive Staphylococcus aureus infections in returning travelers. Am J Trop Med Hyg. 2010 Oct. 83(4):748-50. [Medline]. [Full Text].

  99. Chua K, Laurent F, Coombs G, Grayson ML, Howden BP. Not Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA)! A Clinician's Guide to Community MRSA - Its Evolving Antimicrobial Resistance and Implications for Therapy. Clin Infect Dis. 2011 Jan. 52(1):99-114. [Medline].

  100. Nickerson EK, Wuthiekanun V, Kumar V, Amornchai P, Wongdeethai N, Chheng K. Emergence of Community-Associated Methicillin-Resistant Staphylococcus aureus Carriage in Children in Cambodia. Am J Trop Med Hyg. 2011 Feb. 84(2):313-7. [Medline].

  101. Hamdan-Partida A, Sainz-Espuñes T, Bustos-Martínez J. Characterization and persistence of Staphylococcus aureus strains isolated from the anterior nares and throats of healthy carriers in a Mexican community. J Clin Microbiol. 2010 May. 48(5):1701-5. [Medline].

  102. Muttaiyah S, Coombs G, Pandey S, Reed P, Ritchie S, Lennon D, et al. Incidence, risk factors, and outcomes of Panton-Valentine leukocidin-positive methicillin-susceptible Staphylococcus aureus infections in Auckland, New Zealand. J Clin Microbiol. 2010 Oct. 48(10):3470-4. [Medline]. [Full Text].

  103. Adler A, Givon-Lavi N, Moses AE, Block C, Dagan R. Carriage of community-associated methicillin-resistant Staphylococcus aureus in a cohort of infants in southern Israel: risk factors and molecular features. J Clin Microbiol. 2010 Feb. 48(2):531-8. [Medline]. [Full Text].

  104. Vaska VL, Grimwood K, Gole GA, Nimmo GR, Paterson DL, Nissen MD. Community-associated Methicillin-resistant Staphylococcus aureus Causing Orbital Cellulitis in Australian Children. Pediatr Infect Dis J. 2011 Nov. 30(11):1003-1006. [Medline].

  105. Marra F, Patrick DM, Chong M, McKay R, Hoang L, Bowie WR. Population-based study of the increased incidence of skin and soft tissue infections and associated antimicrobial use. Antimicrob Agents Chemother. 2012 Dec. 56(12):6243-9. [Medline]. [Full Text].

  106. Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis. 2010 Oct 15. 51(8):895-903. [Medline].

  107. Spellberg B. Skin and soft-tissue infections: modern evolution of an ancient problem. Clin Infect Dis. 2010 Oct 15. 51(8):904-6. [Medline]. [Full Text].

  108. Carrillo-Marquez MA, Hulten KG, Hammerman W, Lamberth L, Mason EO, Kaplan SL. Staphylococcus aureus Pneumonia in Children in the Era of Community-acquired Methicillin-resistance at Texas Children's Hospital. Pediatr Infect Dis J. 2011 Jul. 30(7):545-50. [Medline].

  109. Vander Have KL, Karmazyn B, Verma M, Caird MS, Hensinger RN, Farley FA. Community-associated methicillin-resistant Staphylococcus aureus in acute musculoskeletal infection in children: a game changer. J Pediatr Orthop. 2009 Dec. 29(8):927-31. [Medline].

  110. Fretzayas A, Moustaki M, Tsagris V, Brozou T, Nicolaidou P. MRSA blistering distal dactylitis and review of reported cases. Pediatr Dermatol. 2011 Jul-Aug. 28(4):433-5. [Medline].

  111. Carrillo-Marquez MA, Hulten KG, Hammerman W, Mason EO, Kaplan SL. USA300 is the predominant genotype causing Staphylococcus aureus septic arthritis in children. Pediatr Infect Dis J. 2009 Dec. 28(12):1076-80. [Medline].

  112. Carrillo-Marquez MA, Hulten KG, Mason EO, Kaplan SL. Clinical and Molecular Epidemiology of Staphylococcus aureus Catheter-Related Bacteremia in Children. Pediatr Infect Dis J. 2010 May. 29(5):410-4. [Medline].

  113. Jacobson JA, Kasworm E, Daly JA. Risk of developing toxic shock syndrome associated with toxic shock syndrome toxin 1 following nongenital staphylococcal infection. Rev Infect Dis. 1989 Jan-Feb. 11 Suppl 1:S8-13. [Medline].

  114. John CC, Niermann M, Sharon B, Peterson ML, Kranz DM, Schlievert PM. Staphylococcal toxic shock syndrome erythroderma is associated with superantigenicity and hypersensitivity. Clin Infect Dis. 2009 Dec 15. 49(12):1893-6. [Medline]. [Full Text].

  115. Ramirez-Schrempp D, Dorfman DH, Baker WE, Liteplo AS. Ultrasound soft-tissue applications in the pediatric emergency department: to drain or not to drain?. Pediatr Emerg Care. 2009 Jan. 25(1):44-8. [Medline].

  116. Sivitz AB, Lam SH, Ramirez-Schrempp D, Valente JH, Nagdev AD. Effect of bedside ultrasound on management of pediatric soft-tissue infection. J Emerg Med. 2010 Nov. 39(5):637-43. [Medline].

  117. Corey GR. Staphylococcus aureus bacteremia and endocarditis: the role of diagnostic evaluation. Infect Dis Clin Pract. 2011/09. 19(5):307-312.

  118. Kaasch AJ, Fowler VG Jr, Rieg S, Peyerl-Hoffmann G, Birkholz H, Hellmich M, et al. Use of a simple criteria set for guiding echocardiography in nosocomial Staphylococcus aureus bacteremia. Clin Infect Dis. 2011 Jul 1. 53(1):1-9. [Medline]. [Full Text].

  119. Soriano A, Mensa J. Is transesophageal echocardiography dispensable in hospital-acquired Staphylococcus aureus bacteremia?. Clin Infect Dis. 2011 Jul 1. 53(1):10-2. [Medline].

  120. Showler A, Burry L, Bai AD, Steinberg M, Ricciuto DR, Fernandes T, et al. Use of Transthoracic Echocardiography in the Management of Low-Risk Staphylococcus aureus Bacteremia: Results From a Retrospective Multicenter Cohort Study. JACC Cardiovasc Imaging. 2015 Jul 8. [Medline].

  121. Boggs W. Transthoracic Echocardiography Adequate for Ruling Out Infective Endocarditis. http://www.medscape.com/viewarticle/848780. Available at http://www.medscape.com/viewarticle/848780. July 30, 2015; Accessed: August 7, 2015.

  122. Patel Wylie F, Kaplan SL, Mason EO, Allen CH. Needle aspiration for the etiologic diagnosis of children with cellulitis in the era of community-acquired methicillin-resistant Staphylococcus aureus. Clin Pediatr (Phila). 2011 Jun. 50(6):503-7. [Medline].

  123. Duong M, Markwell S, Peter J, Barenkamp S. Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. Ann Emerg Med. 2010 May. 55(5):401-7. [Medline].

  124. Lee MC, Rios AM, Aten MF, Mejias A, Cavuoti D, McCracken GH Jr, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J. 2004 Feb. 23(2):123-7. [Medline].

  125. Rajendran PM, Young D, Maurer T, Chambers H, Perdreau-Remington F, Ro P. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother. 2007 Nov. 51(11):4044-8. [Medline].

  126. Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis. 2007 Mar 15. 44(6):777-84. [Medline].

  127. Karchmer AW. Staphylococcus aureus bacteremia and native valve endocarditis: the role of antimicrobial therapy. Infect Dis Clin Pract. March 2012. 20(2):100-108.

  128. Chen AE, Carroll KC, Diener-West M, Ross T, Ordun J, Goldstein MA, et al. Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections. Pediatrics. 2011 Mar. 127(3):e573-80. [Medline].

  129. McNamara WF, Hartin CW Jr, Escobar MA, Yamout SZ, Lau ST, Lee YH. An alternative to open incision and drainage for community-acquired soft tissue abscesses in children. J Pediatr Surg. 2011 Mar. 46(3):502-6. [Medline].

  130. Keller DM. Staph aureus Scheme Cuts Surgical Infection. Medscape Medical News. Available at http://www.medscape.com/viewarticle/833457. Accessed: October 19, 2014.

  131. Schweizer M, et al. A multicenter intervention to reduce surgical site infections among patients undergoing cardiac operations and total joint arthroplasty (STOP SSI STUDY). Paper presented at IDWeek; October 8-12, 2014; Philadelphia, PA. [Full Text].

  132. Nailor MD, Sobel JD. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Infect Dis Clin N Am. Dec 2009. 23(4):965-82.

  133. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, Török ME. Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis. 2011 Mar. 11(3):208-222. [Medline].

  134. Weisman LE, Thackray HM, Steinhorn RH, Walsh WF, Lassiter HA, Dhanireddy R, et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics. 2011 Aug. 128(2):271-9. [Medline].

  135. Jimenez-Truque N, Thomsen I, Saye E, Creech CB. Should higher vancomycin trough levels be targeted for invasive community-acquired methicillin-resistant Staphylococcus aureus infections in children?. Pediatr Infect Dis J. 2010 Apr. 29(4):368-70. [Medline].

  136. Aguado JM, San-Juan R, Lalueza A, Sanz F, Rodríguez-Otero J, Gómez-Gonzalez C, et al. High Vancomycin MIC and Complicated Methicillin-Susceptible Staphylococcus aureus Bacteremia. Emerg Infect Dis. 2011 Jun. 17(6):1099-102. [Medline].

  137. Lubin AS, Snydman DR, Ruthazer R, Bide P, Golan Y. Predicting high vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus bloodstream infections. Clin Infect Dis. 2011 Apr 15. 52(8):997-1002. [Medline].

  138. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011 Apr 15. 52(8):975-81. [Medline].

  139. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can't get there from here. Clin Infect Dis. 2011 Apr 15. 52(8):969-74. [Medline].

  140. van Hal SJ, Lodise TP, Paterson DL. The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis. Clin Infect Dis. 2012 Mar. 54(6):755-71. [Medline].

  141. Deresinski S. Methicillin-Resistant Staphylococcus aureus and Vancomycin: Minimum Inhibitory Concentration Matters. Clin Infect Dis. 2012 Mar. 54(6):772-4. [Medline].

  142. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, et al. Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study. Clin Infect Dis. 2012 Mar. 54(5):621-9. [Medline].

  143. Ramirez P, Fernández-Barat L, Torres A. New therapy options for MRSA with respiratory infection/pneumonia. Curr Opin Infect Dis. 2012 Apr. 25(2):159-65. [Medline].

  144. Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Pelaez B. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis. 2010 Mar 15. 50(6):821-5. [Medline].

  145. Sanchez Garcia M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA. 2010 Jun 9. 303(22):2260-4. [Medline].

  146. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013 Feb 13. 309(6):559-69. [Medline].

  147. Prokocimer P, Bien P, Deanda C, Pillar CM, Bartizal K. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012 Sep. 56(9):4608-13. [Medline]. [Full Text].

  148. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013 Feb 13. 309(6):559-69. [Medline].

  149. Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014 Jun 5. [Medline].

  150. Lowes, R. New Antibiotic Tedizolid (Sivextro) Approved by FDA. Medscape Medical News. Available at http://www.medscape.com/viewarticle/827168. Accessed: June 26, 2014.

  151. Saravolatz LD, Stein GE, Johnson LB. Telavancin: a novel lipoglycopeptide. Clin Infect Dis. 2009 Dec 15. 49(12):1908-14. [Medline].

  152. Brooks M. FDA OKs Oritavancin (Orbactiv) for Skin Infections. Medscape Medical News. Aug 7 2014. [Full Text].

  153. Moellering RC, Jr, Ferraro MJ. Oritavancin for the treatment of serious gram-positive infections. Clin Infect Dis. 15 April 2012. 54(Suppl 3):S201-S243.

  154. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010 Sep 15. 51(6):641-50. [Medline].

  155. Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2011 May. 52(9):1156-63. [Medline].

  156. Gums JG. Ceftaroline fosamil: a broad-spectrum cephalosporin with methicillin-resistant Staphylococcus aureus activity. Infect Dis Clin Pract. March 2012. 20(2):122-130.

  157. Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Clin Infect Dis. 2012 Sep. 55 Suppl 3:S206-14. [Medline].

  158. Sader HS, Flamm RK, Farrell DJ, Jones RN. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program. Clin Infect Dis. 2012 Sep. 55 Suppl 3:S181-6. [Medline].

  159. Jones RN, Mendes RE, Sader HS, Castanheira M. In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States. Clin Infect Dis. 2011 Jun. 52 Suppl 7:S477-86. [Medline].

  160. Craft JC, Moriarty SR, Clark K, Scott D, Degenhardt TP, Still JG. A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clin Infect Dis. 2011 Jun. 52 Suppl 7:S520-6. [Medline].

  161. Fernandes P, Pereira D. Efforts to support the development of fusidic acid in the United States. Clin Infect Dis. 2011 Jun. 52 Suppl 7:S542-6. [Medline].

  162. Lee AS, Macedo-Vinas M, François P, Renzi G, Schrenzel J, Vernaz N. Impact of combined low-level mupirocin and genotypic chlorhexidine resistance on persistent methicillin-resistant Staphylococcus aureus carriage after decolonization therapy: a case-control study. Clin Infect Dis. 2011 Jun 15. 52(12):1422-30. [Medline].

  163. Jain R, Kralovic SM, Evans ME, et al. Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections. N Engl J Med. 2011 Apr 14. 364(15):1419-30. [Medline].

  164. Robotham JV, Graves N, Cookson BD, Barnett AG, Wilson JA, Edgeworth JD. Screening, isolation, and decolonisation strategies in the control of meticillin resistant Staphylococcus aureus in intensive care units: cost effectiveness evaluation. BMJ. 2011. 343:d5694. [Medline].

  165. Simor AE. Staphylococcal decolonisation: an effective strategy for prevention of infection?. Lancet Infect Dis. 2011 Dec. 11(12):952-62. [Medline].

  166. Fritz SA, Hogan PG, Hayek G, Eisenstein KA, Rodriguez M, Epplin EK, et al. Household Versus Individual Approaches to Eradication of Community-Associated Staphylococcus aureus in Children: A Randomized Trial. Clin Infect Dis. 2012 Mar. 54(6):743-51. [Medline]. [Full Text].

  167. Miller LG. Where We Are With Community-Associated Staphylococcus aureus Prevention--And in the Meantime, What Do We Tell Our Patients?. Clin Infect Dis. 2012 Mar. 54(6):752-4. [Medline].

  168. Kling J. PCR screening cuts in-hospital infection. Medscape Medical News. May 14, 2013. [Full Text].

  169. Milstone AM, Goldner BW, Ross T, Shepard JW, Carroll KC, Perl TM. Methicillin-resistant Staphylococcus aureus colonization and risk of subsequent infection in critically ill children: importance of preventing nosocomial methicillin-resistant Staphylococcus aureus transmission. Clin Infect Dis. 2011 Nov. 53(9):853-9. [Medline]. [Full Text].

  170. Huang SS, Septimus E, Kleinman K, Moody J, Hickok J, Avery TR, et al. Targeted versus Universal Decolonization to Prevent ICU Infection. N Engl J Med. 2013 May 29. [Medline].

  171. Edmond MB, Wenzel RP. Screening Inpatients for MRSA - Case Closed. N Engl J Med. 2013 May 29. [Medline].

  172. Laidman J. MRSA: Universal Decolonization Beats Screening and Isolation. Medscape Medical News. Available at http://www.medscape.com/viewarticle/805005. Accessed: June 11, 2013.

  173. Shenoy ES, Kim J, Rosenberg ES, Cotter JA, Lee H, Walensky RP, et al. Discontinuation of Contact Precautions for Methicillin-Resistant Staphylococcus aureus: A Randomized Controlled Trial Comparing Passive and Active Screening With Culture and Polymerase Chain Reaction. Clin Infect Dis. 2013 Jul. 57(2):176-84. [Medline]. [Full Text].

  174. Lin Y-C, Peterson ML. New insights into the prevention of staphylococcal infections and toxic shock syndrome. Expert Rev Clin Pharmacol. 2010. 3:753-767.

  175. Huda T, Nair H, Theodoratou E, Zgaga L, Fattom A, El Arifeen S, et al. An evaluation of the emerging vaccines and immunotherapy against staphylococcal pneumonia in children. BMC Public Health. 2011 Apr 13. 11 Suppl 3:S27. [Medline]. [Full Text].

  176. Daum RS, Spellberg B. Progress Toward a Staphylococcus aureus Vaccine. Clin Infect Dis. 2012 Feb. 54(4):560-7. [Medline].

  177. Theilacker C, Kropec A, Hammer F, Sava I, Wobser D, Sakinc T. Protection Against Staphylococcus aureus by Antibody to the Polyglycerolphosphate Backbone of Heterologous Lipoteichoic Acid. J Infect Dis. 2012 Apr. 205(7):1076-85. [Medline].

  178. Proctor RA. Challenges for a Universal Staphylococcus aureus Vaccine. Clin Infect Dis. 2012 Apr. 54(8):1179-86. [Medline].

  179. Anderson AS, Scully IL, Timofeyeva Y, Murphy E, McNeil LK, Mininni T, et al. Staphylococcus aureus Manganese Transport Protein C Is a Highly Conserved Cell Surface Protein That Elicits Protective Immunity Against S. aureus and Staphylococcus epidermidis. J Infect Dis. 2012 Jun. 205(11):1688-96. [Medline]. [Full Text].

  180. Fritz SA, Tiemann KM, Hogan PG, Epplin EK, Rodriguez M, Al-Zubeidi DN, et al. A Serologic Correlate of Protective Immunity Against Community-Onset Staphylococcus aureus Infection. Clin Infect Dis. 2013 Jun. 56(11):1554-61. [Medline]. [Full Text].

  181. McNeil JC, Hulten KG, Kaplan SL, Mahoney DH, Mason EO. Staphylococcus aureus Infections in Pediatric Oncology Patients: High Rates of Antimicrobial Resistance, Antiseptic Tolerance and Complications. Pediatr Infect Dis J. 2013 Feb. 32(2):124-8. [Medline].

  182. Creel AM, Durham SH, Benner KW, Alten JA, Winkler MK. Severe invasive community-associated methicillin-resistant Staphylococcus aureus infections in previously healthy children. Pediatr Crit Care Med. 2009 May. 10(3):323-7. [Medline].

  183. Vergnano S, Menson E, Smith Z, Kennea N, Embleton N, Clarke P. Characteristics of Invasive Staphylococcus aureus in United Kingdom Neonatal Units. Pediatr Infect Dis J. 2011 Oct. 30(10):850-4. [Medline].

  184. Menif K, Bouziri A, Khaldi A, Hamdi A, Belhadj S, Borgi A, et al. Community-associated methicillin-resistant Staphylococcus aureus infections in a pediatric intensive care unit. J Infect Dev Ctries. 2011 Aug 12. 5(8):587-91. [Medline].

  185. Heinrich N, Mueller A, Bartmann P, Simon A, Bierbaum G, Engelhart S. Successful management of an MRSA outbreak in a neonatal intensive care unit. Eur J Clin Microbiol Infect Dis. 2011 Jul. 30(7):909-13. [Medline].

  186. Woodlief RS, Markowitz JE. Unrecognized invasive infection in a neonate colonized with methicillin-resistant staphylococcus aureus. J Pediatr. 2009 Dec. 155(6):943-943.e1. [Medline].

  187. Arora P, Kalra VK, Pappas A. Multiple brain abscesses in a neonate after blood stream infection with methicillin-resistant Staphylococcus aureus. J Pediatr. 2012 Sep. 161(3):563-563.e1. [Medline].

  188. Niemann S, Ehrhardt C, Medina E, Warnking K, Tuchscherr L, Heitmann V, et al. Combined action of influenza virus and Staphylococcus aureus panton-valentine leukocidin provokes severe lung epithelium damage. J Infect Dis. 2012 Oct 1. 206(7):1138-48. [Medline]. [Full Text].

  189. Faden H, Gill S, Lesse A. Impact of Management and Bacterial Genomics on Outcomes of Staphylococcus aureus Bacteremia in Children. Clin Pediatr (Phila). 2011 Jun 17. [Medline].

  190. Mejer N, Westh H, Schønheyder HC, Jensen AG, Larsen AR, Skov R, et al. Stable incidence and continued improvement in short term mortality of Staphylococcus aureus bacteraemia between 1995 and 2008. BMC Infect Dis. 2012 Oct 17. 12:260. [Medline]. [Full Text].

  191. Sengupta A, Rand C, Perl TM, Milstone AM. Knowledge, Awareness, and Attitudes Regarding Methicillin-Resistant Staphylococcus Aureus among Caregivers of Hospitalized Children. J Pediatr. 2011 Mar. 158(3):416-21. [Medline].

  192. US Food and Drug Administration. FDA Drug Safety Communication: Serious CNS reactions possible when linezolid (Zyvox®) is given to patients taking certain psychiatric medications. Available at http://www.fda.gov/Drugs/DrugSafety/ucm265305.htm. Accessed: July 27, 2011.

  193. Abrahamian FM, Moran GJ. Methicillin-resistant Staphylococcus aureus infections. N Engl J Med. 2007 Nov 15. 357(20):2090; author reply 2090. [Medline].

  194. American Academy of Pediatrics. Staphylococcal infections. Report of the Committee on Infectious Diseases. 28th. American Academy of Pediatrics; 2009. 601-15.

  195. Anderson DJ, Sexton DJ, Kanafani ZA, Auten G, Kaye KS. Severe surgical site infection in community hospitals: epidemiology, key procedures, and the changing prevalence of methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol. 2007 Sep. 28(9):1047-53. [Medline].

  196. Antaya RJ, Robinson DM. Blisters and pustules in the newborn. Pediatr Ann. 2010 Oct. 39(10):635-45. [Medline].

  197. Atanaskova N, Tomecki KJ. Innovative management of recurrent furunculosis. Dermatol Clin. 2010 Jul. 28(3):479-87. [Medline].

  198. Awad SS, Elhabash SI, Lee L, Farrow B, Berger DH. Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy. Am J Surg. 2007 Nov. 194(5):606-10. [Medline].

  199. Baartmans MG, Maas MH, Dokter J. Neonate with staphylococcal scalded skin syndrome. Arch Dis Child Fetal Neonatal Ed. 2006 Jan. 91(1):F25. [Medline]. [Full Text].

  200. Baker CJ. Why has methicillin-resistant Staphylococcus aureus become such a successful pathogen? A pediatric perspective. Infect Dis Clin Pract. 2010 July. 18(4):231-4.

  201. Barry W, Hudgins L, Donta ST, Pesanti EL. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA. 1992 Jun 24. 267(24):3315-6. [Medline].

  202. Becker SS, Russell PT, Duncavage JA, Creech CB. Current issues in the management of sinonasal methicillin-resistant Staphylococcus aureus. Curr Opin Otolaryngol Head Neck Surg. 2009 Feb. 17(1):2-5. [Medline].

  203. Berk DR, Bayliss SJ. MRSA, staphylococcal scalded skin syndrome, and other cutaneous bacterial emergencies. Pediatr Ann. 2010 Oct. 39(10):627-33. [Medline].

  204. Bhalla A, Aron DC, Donskey CJ. Staphylococcus aureus intestinal colonization is associated with increased frequency of S. aureus on skin of hospitalized patients. BMC Infect Dis. 2007. 7:105. [Medline].

  205. Bian L, Strzyz P, Jonsson IM, Erlandsson M, Hellvard A, Brisslert M. S100A4 Deficiency Is Associated With Efficient Bacterial Clearance and Protects Against Joint Destruction During Staphylococcal Infection. J Infect Dis. 2011 Sep. 204(5):722-30. [Medline].

  206. Bode LG, Kluytmans JA, Wertheim HF, Bogaers D, Vandenbroucke-Grauls CM, Roosendaal R. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med. 2010 Jan 7. 362(1):9-17. [Medline].

  207. Boucher H, Miller LG, Razonable RR. Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2010 Sep 15. 51 Suppl 2:S183-97. [Medline].

  208. Brinsley-Rainisch KJ, Cochran RL, Pearson ML. Dermatologists' perceptions and practices related to community-associated methicillin-resistant Staphylococcus aureus infections. Am J Infect Control. 2008 Nov. 36(9):668-71. [Medline].

  209. Browne LP, Mason EO, Kaplan SL, Cassady CI, Krishnamurthy R, Guillerman RP. Optimal imaging strategy for community-acquired Staphylococcus aureus musculoskeletal infections in children. Pediatr Radiol. 2008 Aug. 38(8):841-7. [Medline].

  210. Cadilla A, David MZ, Daum RS, Boyle-Vavra S. Association of high-level mupirocin resistance and multidrug-resistant methicillin-resistant Staphylococcus aureus at an academic center in the midwestern United States. J Clin Microbiol. 2011 Jan. 49(1):95-100. [Medline].

  211. Calfee DP. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, and other Gram-positives in healthcare. Curr Opin Infect Dis. 2012 Aug. 25(4):385-94. [Medline].

  212. Campbell W, Hendrix E, Schwalbe R, Fattom A, Edelman R. Head-injured patients who are nasal carriers of Staphylococcus aureus are at high risk for Staphylococcus aureus pneumonia. Crit Care Med. 1999 Apr. 27(4):798-801. [Medline].

  213. Casas I, Sopena N, Esteve M, et al. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus carriage at hospital admission. Infect Control Hosp Epidemiol. 2007 Nov. 28(11):1314-7. [Medline].

  214. CDC. Community-associated methicillin-resistant Staphylococcus aureus infection among healthy newborns--Chicago and Los Angeles County, 2004. MMWR Morb Mortal Wkly Rep. 2006 Mar 31. 55(12):329-32. [Medline].

  215. CDC. From the Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus--Minnesota and North Dakota, 1997-1999. JAMA. 1999 Sep 22-29. 282(12):1123-5. [Medline].

  216. CDC. Outbreak of staphylococcal food poisoning associated with precooked ham--Florida, 1997. MMWR Morb Mortal Wkly Rep. 1997 Dec 19. 46(50):1189-91. [Medline].

  217. Chambers HF. Pathogenesis of staphylococcal infection: a manner of expression. J Infect Dis. 2009 Feb 1. 199(3):291-3. [Medline].

  218. Chen CJ, Su LH, Lin TY, Huang YC. Molecular analysis of repeated methicillin-resistant Staphylococcus aureus infections in children. PLoS One. 2010 Dec 28. 5(12):e14431. [Medline]. [Full Text].

  219. Chen L, Shopsin B, Zhao Y, Smyth D, Wasserman GA, Fang C, et al. Real-time nucleic acid sequence-based amplification assay for rapid detection and quantification of agr functionality in clinical Staphylococcus aureus isolates. J Clin Microbiol. 2012 Mar. 50(3):657-61. [Medline]. [Full Text].

  220. Chen SY, Liao CH, Wang JL, Chiang WC, Lai MS, Chie WC, et al. Methicillin-resistant Staphylococcus aureus (MRSA) staphylococcal cassette chromosome mec genotype effects outcomes of patients with healthcare-associated MRSA bacteremia independently of vancomycin minimum inhibitory concentration. Clin Infect Dis. 2012 Nov 15. 55(10):1329-37. [Medline].

  221. Chen WL, Chang WN, Chen YS, Hsieh KS, Chen CK, Peng NJ, et al. Acute community-acquired osteoarticular infections in children: high incidence of concomitant bone and joint involvement. J Microbiol Immunol Infect. 2010 Aug. 43(4):332-8. [Medline].

  222. Cohen AL, Naseri I, Pinell X, Sobol SE, Gorwitz R. Treatment of methicillin-resistant Staphylococcus aureus pediatric head and neck infections: results of a national survey of otolaryngologists in the United States. J Otolaryngol Head Neck Surg. 2010 Aug. 39(4):468-73. [Medline].

  223. Cohen-Wolkowiez M, Watt KM, Hornik CP, Benjamin DK Jr, Smith PB. Pharmacokinetics and tolerability of single-dose daptomycin in young infants. Pediatr Infect Dis J. 2012 Sep. 31(9):935-7. [Medline]. [Full Text].

  224. Copley LA. Pediatric musculoskeletal infection: trends and antibiotic recommendations. J Am Acad Orthop Surg. 2009 Oct. 17(10):618-26. [Medline].

  225. Dancer SJ. Importance of the environment in meticillin-resistant Staphylococcus aureus acquisition: the case for hospital cleaning. Lancet Infect Dis. 2008 Feb. 8(2):101-13. [Medline].

  226. Darouiche RO, Wall MJ Jr, Itani KM, Otterson MF, Webb AL, Carrick MM. Chlorhexidine-Alcohol versus Povidone-Iodine for Surgical-Site Antisepsis. N Engl J Med. 2010 Jan 7. 362(1):18-26. [Medline].

  227. Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA. 2010 Jun 16. 303(23):2386-92. [Medline].

  228. Datta F, Erb T, Heininger U, et al. A multicenter, cross-sectional study on the prevalence and risk factors for nasal colonization with Staphylococcus aureus in patients admitted to children's hospitals in Switzerland. Clin Infect Dis. 2008 Oct 1. 47(7):923-6. [Medline].

  229. Daum RS. Removing the golden coat of Staphylococcus aureus. N Engl J Med. 2008 Jul 3. 359(1):85-7. [Medline].

  230. David MD, Kearns AM, Gossain S, Ganner M, Holmes A. Community-associated meticillin-resistant Staphylococcus aureus: nosocomial transmission in a neonatal unit. J Hosp Infect. 2006 Nov. 64(3):244-50. [Medline].

  231. David MZ, Rudolph KM, Hennessy TW, Zychowski DL, Asthi K, Boyle-Vavra S, et al. MRSA USA300 at Alaska native medical center, anchorage, Alaska, USA, 2000-2006. Emerg Infect Dis. 2012 Jan. 18(1):105-8. [Medline].

  232. Davis MF, Iverson SA, Baron P, Vasse A, Silbergeld EK, Lautenbach E. Household transmission of meticillin-resistant Staphylococcus aureus and other staphylococci. Lancet Infect Dis. 2012 Sep. 12(9):703-16. [Medline].

  233. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011 Jul 15. 53(2):158-63. [Medline].

  234. Dohin B, Gillet Y, Kohler R, et al. Pediatric Bone and Joint Infections Caused by Panton-Valentine Leukocidin-Positive Staphylococcus aureus. Pediatr Infect Dis J. 2007 Nov. 26(11):1042-1048. [Medline].

  235. Dukic VM, David MZ, Lauderdale DS. Internet queries and methicillin-resistant Staphylococcus aureus surveillance. Emerg Infect Dis. 2011 Jun. 17(6):1068-70. [Medline].

  236. Edelsberg J, Taneja C, Zervos M, Haque N, Moore C, Reyes K. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis. 2009 Sep. 15(9):1516-8. [Medline]. [Full Text].

  237. Eron L. Medscape Reference: the future of outpatient therapy?. Clin Infect Dis. 2010 Sep 15. 51 Suppl 2:S224-30. [Medline].

  238. Faden H. Mastitis in children from birth to 17 years. Pediatr Infect Dis J. 2005 Dec. 24(12):1113. [Medline].

  239. Faden H, Rose R, Lesse A, Hollands C, Dryja D, Glick PL. Clinical and molecular characteristics of staphylococcal skin abscesses in children. J Pediatr. 2007 Dec. 151(6):700-3. [Medline].

  240. Fagon J, Patrick H, Haas DW, Torres A, Gibert C, Cheadle WG, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med. 2000 Mar. 161(3 Pt 1):753-62. [Medline].

  241. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis. 2008 Jan. 8(1):53-66. [Medline].

  242. Farrell AM. Staphylococcal scalded-skin syndrome. Lancet. 1999 Sep 11. 354(9182):880-1. [Medline].

  243. Feigen RD, Cherry JD. Coagulase positive staphylococcal infections. In: Feigen RD, Cherry JD, eds. Textbook of Pediatric Infectious Disease. Philadelphia, Pa: WB Saunders Co; 1998. Chapters 32,64,85.

  244. Fergie J, Purcell K. The Treatment of Community-Acquired Methicillin-Resistant Staphylococcus aureus Infections. Pediatr Infect Dis J. 2008 Jan. 27(1):67-68. [Medline].

  245. Fernandez Guerrero ML, Lopez JG, Artiz V, et al. Left-sided endocarditis caused by Staphylococcus aureus: a comparison of clinical and prognostic factors of patients with native and prosthetic valve endocarditis. Infect Dis Clin Pract. September 2010. 18(5):308-12.

  246. Fernandez M, Carrol CL, Baker CJ. Discitis and vertebral osteomyelitis in children: an 18-year review. Pediatrics. 2000 Jun. 105(6):1299-304. [Medline].

  247. Ferrara AM. Treatment of hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2007 Jul. 30(1):19-24. [Medline].

  248. Finks J, Wells E, Dyke TL, Husain N, Plizga L, Heddurshetti R. Vancomycin-resistant Staphylococcus aureus, Michigan, USA, 2007. Emerg Infect Dis. 2009 Jun. 15(6):943-5. [Medline].

  249. Fortunov RM, Hulten KG, Allen CH, et al. NASAL STAPHYLOCOCCUS AUREUS COLONIZATION AMONG MOTHERS OF TERM AND LATE PRETERM PREVIOUSLY HEALTHY NEONATES WITH COMMUNITY-ACQUIRED STAPHYLOCOCCUS AUREUS INFECTIONS. Pediatr Infect Dis J. 2010 Oct 13. [Medline].

  250. Fortunov RM, Hulten KG, Hammerman WA, Mason EO Jr, Kaplan SL. Evaluation and Treatment of Community-Acquired Staphylococcus aureus Infections in Term and Late-Preterm Previously Healthy Neonates. Pediatrics. 2007 Nov. 120(5):937-945. [Medline].

  251. Frank AL. Staphylococcus aureus: a moving target. J Pediatr. 2007 Dec. 151(6):561-3. [Medline].

  252. Fritz SA, Garbutt J, Elward A, Shannon W, Storch GA. Prevalence of and risk factors for community-acquired methicillin-resistant and methicillin-sensitive staphylococcus aureus colonization in children seen in a practice-based research network. Pediatrics. 2008 Jun. 121(6):1090-8. [Medline].

  253. Fritz SA, Hogan PG, Hayek G, Eisenstein KA, Rodriguez M, Krauss M, et al. Staphylococcus aureus colonization in children with community-associated Staphylococcus aureus skin infections and their household contacts. Arch Pediatr Adolesc Med. 2012 Jun 1. 166(6):551-7. [Medline]. [Full Text].

  254. Frodermann V, Chau TA, Sayedyahossein S, Toth JM, Heinrichs DE, Madrenas J. A Modulatory Interleukin-10 Response to Staphylococcal Peptidoglycan Prevents Th1/Th17 Adaptive Immunity to Staphylococcus aureus. J Infect Dis. 2011 Jul. 204(2):253-62. [Medline].

  255. Fu CM, Tseng WP, Chiang WC, Lai MS, Chie WC, Chou HC. Occult Staphylococcus aureus Bacteremia in Adult Emergency Department Patients: Rare but Important. Clin Infect Dis. 2012 Jun. 54(11):1536-44. [Medline].

  256. Gafur OA, Copley LA, Hollmig ST, Browne RH, Thornton LA, Crawford SE. The impact of the current epidemiology of pediatric musculoskeletal infection on evaluation and treatment guidelines. J Pediatr Orthop. 2008 Oct-Nov. 28(7):777-85. [Medline].

  257. Gerber JS, Coffin SE, Smathers SA, Zaoutis TE. Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children's hospitals in the United States. Clin Infect Dis. 2009 Jul 1. 49(1):65-71. [Medline].

  258. Geva A, Wright SB, Baldini LM, Smallcomb JA, Safran C, Gray JE. Spread of Methicillin-Resistant Staphylococcus aureus in a Large Tertiary NICU: Network Analysis. Pediatrics. 2011 Nov. 128(5):e1173-e1180. [Medline].

  259. Gillon JE, Cassat JE, Di Pentima MC. Validation of two vancomycin nomograms in patients 10 years of age and older. J Clin Pharmacol. 2014 Jan. 54(1):35-8. [Medline].

  260. Gonzalez BE, Kaplan SL. Severe staphylococcal infections in children. Pediatr Ann. 2008 Oct. 37(10):686-93. [Medline].

  261. Gonzalez BE, Mon RA. Staphylococcus aureus infections in adolescents. Adolesc Med State Art Rev. 2010 Aug. 21(2):318-31, x. [Medline].

  262. Gonzalez BE, Teruya J, Mahoney DH Jr, et al. Venous thrombosis associated with staphylococcal osteomyelitis in children. Pediatrics. 2006 May. 117(5):1673-9. [Medline].

  263. Gorwitz RJ. A Review of Community-Associated Methicillin-Resistant Staphylococcus aureus Skin and Soft Tissue Infections. Pediatr Infect Dis J. 2008 Jan. 27(1):1-7. [Medline].

  264. Gorwitz RJ. Understanding the Success of Methicillin-Resistant Staphylococcus aureus Strains Causing Epidemic Disease in the Community. J Infect Dis. 2008 Jan 15. 197(2):179-82. [Medline].

  265. Greene JN. Infections Related to Vascular Access Devices. Cancer Control. 1996 Oct. 3(5):456-464. [Medline].

  266. Gregory ML, Eichenwald EC, Puopolo KM. Seven-year experience with a surveillance program to reduce methicillin-resistant Staphylococcus aureus colonization in a neonatal intensive care unit. Pediatrics. 2009 May. 123(5):e790-6. [Medline].

  267. Gutierrez K, Halpern MS, Sarnquist C, Soni S, Arroyo AC, Maldonado Y. Staphylococcal infections in children, California, USA, 1985-2009. Emerg Infect Dis. 2013 Jan. 19(1):10-20; quiz 185. [Medline]. [Full Text].

  268. Hamilton SM, Bryant AE, Carroll KC, et al. In vitro production of panton-valentine leukocidin among strains of methicillin-resistant Staphylococcus aureus causing diverse infections. Clin Infect Dis. 2007 Dec 15. 45(12):1550-8. [Medline].

  269. Hanson MR, Chung CL. Antibiotic selection for MRSA: case presentations and review of the literature. J Drugs Dermatol. 2009 Mar. 8(3):281-6. [Medline].

  270. Haran KP, Godden SM, Boxrud D, Jawahir S, Bender JB, Sreevatsan S. Prevalence and characterization of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, isolated from bulk tank milk from Minnesota dairy farms. J Clin Microbiol. 2012 Mar. 50(3):688-95. [Medline].

  271. Heininger U, Datta F, Gervaix A, et al. Prevalence of nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) in children a multicenter cross-sectional study. Pediatr Infect Dis J. 2007 Jun. 26(6):544-6. [Medline].

  272. Henningsson L, Jirholt P, Bogestål YR, Eneljung T, Adiels M, Lindholm C. Interleukin 15 mediates joint destruction in Staphylococcus aureus arthritis. J Infect Dis. 2012 Sep 1. 206(5):687-96. [Medline].

  273. Herigon JC, Hersh AL, Gerber JS, Zaoutis TE, Newland JG. Antibiotic Management of Staphylococcus aureus Infections in US Children's Hospitals, 1999-2008. Pediatrics. 2010 May 17. [Medline].

  274. Hetem DJ, de Ruiter SC, Buiting AG, Kluytmans JA, Thijsen SF, Vlaminckx BJ. Preventing Staphylococcus aureus bacteremia and sepsis in patients with Staphylococcus aureus colonization of intravascular catheters: a retrospective multicenter study and meta-analysis. Medicine (Baltimore). 2011 Jul. 90(4):284-8. [Medline].

  275. Hewlett AL, Falk PS, Hughes KS, Mayhall CG. Epidemiology of methicillin-resistant Staphylococcus aureus in a university medical center day care facility. Infect Control Hosp Epidemiol. 2009 Oct. 30(10):985-92. [Medline].

  276. Hogue JS, Buttke P, Braun LE, Fairchok MP. Mupirocin resistance related to increasing mupirocin use in clinical isolates of methicillin-resistant Staphylococcus aureus in a pediatric population. J Clin Microbiol. 2010 Jul. 48(7):2599-600. [Medline]. [Full Text].

  277. Homma S, Sagawa Y, Ito M, Ohno T, Toda G. Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. Clin Exp Immunol. 2006 Apr. 144(1):41-7. [Medline].

  278. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010 Jan. 23(1):99-139. [Medline]. [Full Text].

  279. Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics. 2009 May. 123(5):e808-14. [Medline].

  280. Huang YC, Ho CF, Chen CJ, Su LH, Lin TY. Nasal Carriage of Methicillin-Resistant Staphylococcus aureus in Household Contacts of Children With Community-Acquired Diseases in Taiwan. Pediatr Infect Dis J. 2007 Nov. 26(11):1066-1068. [Medline].

  281. Hulten KG, Kaplan SL, Gonzalez BE, et al. Three-year surveillance of community onset health care-associated staphylococcus aureus infections in children. Pediatr Infect Dis J. 2006 Apr. 25(4):349-53. [Medline].

  282. Hussain A, Robinson G, Malkin J, Duthie M, Kearns A, Perera N. Purpura fulminans in a child secondary to Panton-Valentine leukocidin-producing Staphylococcus aureus. J Med Microbiol. 2007 Oct. 56(Pt 10):1407-9. [Medline].

  283. Jaggi P, Paule SM, Peterson LR, Tan TQ. Characteristics of Staphylococcus aureus infections, Chicago Pediatric Hospital. Emerg Infect Dis. 2007 Feb. 13(2):311-4. [Medline].

  284. Jensen JU, Jensen ET, Larsen AR, et al. Control of a methicillin-resistant Staphylococcus aureus (MRSA) outbreak in a day-care institution. J Hosp Infect. 2006 May. 63(1):84-92. [Medline].

  285. Jeyaratnam D, Reid C, Kearns A, Klein J. Community associated MRSA: an alert to paediatricians. Arch Dis Child. 2006 Jun. 91(6):511-2. [Medline].

  286. Jimenez-Truque N, Tedeschi S, Saye EJ, McKenna BD, Langdon W, Wright JP. Relationship Between Maternal and Neonatal Staphylococcus aureus Colonization. Pediatrics. 2012 Apr 2. [Medline].

  287. John Jr JF, Lindsay JA. Clones and Drones: Do Variants of Panton-Valentine Leukocidin Extend the Reach of Community-Associated Methicillin-Resistant Staphylococcus aureus?. J Infect Dis. 2008 Jan 4. [Medline].

  288. Jones RN. Key considerations in the treatment of complicated staphylococcal infections. Clin Microbiol Infect. 2008 Mar. 14 Suppl 2:3-9. [Medline].

  289. Kahl B, Herrmann M, Everding AS, et al. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis. 1998 Apr. 177(4):1023-9. [Medline].

  290. Kaplan SL. Challenges in the evaluation and management of bone and joint infections and the role of new antibiotics for gram positive infections. Adv Exp Med Biol. 2009. 634:111-20. [Medline].

  291. Kaplan SL. Community-acquired methicillin-resistant Staphylococcus aureus infections in children. Semin Pediatr Infect Dis. 2006 Jul. 17(3):113-9. [Medline].

  292. Kapoor V, Travadi J, Braye S. Staphylococcal scalded skin syndrome in an extremely premature neonate: a case report with a brief review of literature. J Paediatr Child Health. 2008 Jun. 44(6):374-6. [Medline].

  293. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, Braughton KR. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis. 2010 Oct 1. 202(7):1050-8. [Medline].

  294. Kern WV. Management of Staphylococcus aureus bacteremia and endocarditis: progresses and challenges. Curr Opin Infect Dis. 2010 Aug. 23(4):346-58. [Medline].

  295. Khangura S, Wallace J, Kissoon N, Kodeeswaran T. Management of cellulitis in a pediatric emergency department. Pediatr Emerg Care. 2007 Nov. 23(11):805-11. [Medline].

  296. Khawcharoenporn T, Tice AD, Grandinetti A, Chow D. Risk factors for community-associated methicillin-resistant Staphylococcus aureus cellulitis--and the value of recognition. Hawaii Med J. 2010 Oct. 69(10):232-6. [Medline].

  297. Klein E, Smith DL, Laxminarayan R. Community-associated Methicillin-Resistant Staphylococcus aureus in Outpatients, United States, 1999-2006. Emerg Infect Dis. 2009 Dec. 15(12):1925-30. [Medline].

  298. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis. 2007 Dec. 13(12):1840-6. [Medline].

  299. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007 Oct 17. 298(15):1763-71. [Medline].

  300. Krugman. Staphylococcus Aureus. In: Katz SL, Gershon AA, Hotez PJ, eds. Krugman's Infectious Diseases of Children. 10th. St. Louis, Mo: CV Mosby; 1998. Chapter 19.

  301. Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis. 2006 Jan 15. 193(2):172-9. [Medline].

  302. Kwiecinski J, Josefsson E, Mitchell J, Higgins J, Magnusson M, Foster T, et al. Activation of plasminogen by staphylokinase reduces the severity of Staphylococcus aureus systemic infection. J Infect Dis. 2010 Oct 1. 202(7):1041-9. [Medline].

  303. Köser CU, Holden MT, Ellington MJ, Cartwright EJ, Brown NM, Ogilvy-Stuart AL, et al. Rapid whole-genome sequencing for investigation of a neonatal MRSA outbreak. N Engl J Med. 2012 Jun 14. 366(24):2267-75. [Medline].

  304. Köser CU, Holden MT, Ellington MJ, Cartwright EJ, Brown NM, Ogilvy-Stuart AL, et al. Rapid whole-genome sequencing for investigation of a neonatal MRSA outbreak. N Engl J Med. 2012 Jun 14. 366(24):2267-75. [Medline].

  305. Labbe JL, Peres O, Leclair O, et al. Acute osteomyelitis in children: the pathogenesis revisited?. Orthop Traumatol Surg Res. 2010 May. 96(3):268-75. [Medline].

  306. Ladhani S, Joannou CL. Difficulties in diagnosis and management of the staphylococcal scalded skin syndrome. Pediatr Infect Dis J. 2000 Sep. 19(9):819-21. [Medline].

  307. Laing IA, Gibb AP, McCallum A. Controlling an outbreak of MRSA in the neonatal unit: a steep learning curve. Arch Dis Child Fetal Neonatal Ed. 2009 Jul. 94(4):F307-10. [Medline].

  308. Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med. 2007 Oct. 120(10 Suppl 1):S13-20. [Medline].

  309. Lareau SM, Meyn L, Beigi RH. Methicillin-resistant Staphylococcus aureus as the most common cause of perineal abscesses. Infect Dis Clin Pract. July 2010. 18(4):258-60.

  310. Laurent F, Chardon H, Haenni M, Bes M, Reverdy ME, Madec JY, et al. MRSA harboring mecA variant gene mecC, France. Emerg Infect Dis. 2012 Sep. 18(9):1465-7. [Medline]. [Full Text].

  311. Lee CY, Chen PY, Huang FL, Lin CF. Microbiologic spectrum and susceptibility pattern of clinical isolates from the pediatric intensive care unit in a single medical center - 6 years' experience. J Microbiol Immunol Infect. 2009 Apr. 42(2):160-5. [Medline].

  312. Lee TC, Carrick MM, Scott BG, Hodges JC, Pham HQ. Incidence and clinical characteristics of methicillin-resistant Staphylococcus aureus necrotizing fasciitis in a large urban hospital. Am J Surg. 2007 Dec. 194(6):809-12; discussion 812-3. [Medline].

  313. Leshem E, Maayan-Metzger A, Rahav G, Dolitzki M, Kuint J, Roytman Y. Transmission of Staphylococcus aureus From Mothers to Newborns. Pediatr Infect Dis J. 2012 Apr. 31(4):360-363. [Medline].

  314. Lessa FC, Edwards JR, Fridkin SK, Tenover FC, Horan TC, Gorwitz RJ. Trends in Incidence of Late-Onset Methicillin-Resistant Staphylococcus aureus Infection in Neonatal Intensive Care Units: Data From the National Nosocomial Infections Surveillance System, 1995-2004. Pediatr Infect Dis J. 2009 Jul. 28(7):577-581. [Medline].

  315. Lessa FC, Mu Y, Ray SM, Dumyati G, Bulens S, Gorwitz RJ, et al. Impact of USA300 methicillin-resistant Staphylococcus aureus on clinical outcomes of patients with pneumonia or central line-associated bloodstream infections. Clin Infect Dis. 2012 Jul. 55(2):232-41. [Medline].

  316. Levine DP, Lamp KC. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Am J Med. 2007 Oct. 120(10 Suppl 1):S28-33. [Medline].

  317. Li M, Diep BA, Villaruz AE, et al. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci U S A. 2009 Apr 7. 106(14):5883-8. [Medline]. [Full Text].

  318. Lin MH, Chang FR, Hua MY, Wu YC, Liu ST. Inhibitory effects of 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranose on biofilm formation by Staphylococcus aureus. Antimicrob Agents Chemother. 2011 Mar. 55(3):1021-7. [Medline]. [Full Text].

  319. Lipsky BA, Weigelt JA, Gupta V, Killian A, Peng MM. Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. Infect Control Hosp Epidemiol. 2007 Nov. 28(11):1290-8. [Medline].

  320. Lo WT, Tang CS, Chen SJ, Huang CF, Tseng MH, Wang CC. Panton-Valentine Leukocidin Is Associated with Exacerbated Skin Manifestations and Inflammatory Response in Children with Community-Associated Staphylococcal Scarlet Fever. Clin Infect Dis. 2009 Sep 2. [Medline].

  321. Loughman JA, Fritz SA, Storch GA, Hunstad DA. Virulence Gene Expression in Human Community-Acquired Staphylococcus aureus Infection. J Infect Dis. 2009 Feb 1. 199(3):294-301. [Medline].

  322. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998 Aug 20. 339(8):520-32. [Medline].

  323. Lucet JC, Regnier B. Screening and decolonization: does methicillin-susceptible Staphylococcus aureus hold lessons for methicillin-resistant S. aureus?. Clin Infect Dis. 2010 Sep 1. 51(5):585-90. [Medline].

  324. Mangini E, Segal-Maurer S, Burns J, et al. Impact of contact and droplet precautions on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus infection. Infect Control Hosp Epidemiol. 2007 Nov. 28(11):1261-6. [Medline].

  325. Maranan MC, Moreira B, Boyle-Vavra S, Daum RS. Antimicrobial resistance in staphylococci. Epidemiology, molecular mechanisms, and clinical relevance. Infect Dis Clin North Am. 1997 Dec. 11(4):813-49. [Medline].

  326. Maraqa NF, Aigbivbalu L, Masnita-Iusan C, Wludyka P, Shareef Z, Bailey C. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus colonization and infection among infants at a level III neonatal intensive care unit. Am J Infect Control. 2011 Feb. 39(1):35-41. [Medline].

  327. Maree CL, Daum RS, Boyle-Vavra S, Matayoshi K, Miller LG. Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections. Emerg Infect Dis. 2007 Feb. 13(2):236-42. [Medline].

  328. Maree CL, Eells SJ, Tan J, Bancroft EA, Malek M, Harawa NT. Risk factors for infection and colonization with community-associated methicillin-resistant Staphylococcus aureus in the Los Angeles County jail: a case-control study. Clin Infect Dis. 2010 Dec 1. 51(11):1248-57. [Medline].

  329. Marom D, Levy I, Gutwein O, Birk E, Ashkenazi S. Healthcare-associated Versus Community-associated Infective Endocarditis in Children. Pediatr Infect Dis J. 2011 Jul. 30(7):585-8. [Medline].

  330. Masiuk H, Kopron K, Grumann D, et al. Association of recurrent furunculosis with Panton-Valentine leukocidin and the genetic background of Staphylococcus aureus. J Clin Microbiol. 2010 May. 48(5):1527-35. [Medline]. [Full Text].

  331. McCaskill ML, Mason EO Jr, Kaplan SL, Hammerman W, Lamberth LB, Hulten KG. Increase of the USA300 clone among community-acquired methicillin-susceptible Staphylococcus aureus causing invasive infections. Pediatr Infect Dis J. 2007 Dec. 26(12):1122-7. [Medline].

  332. McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A, Le J. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr. 2011 Mar. 158(3):422-6. [Medline].

  333. McNamara D. Vancomycin dosing nomograms inadequate for tweens and teens. Medscape Medical News. January 13, 2014. [Full Text].

  334. McNeil JC, Hulten KG, Kaplan SL, Schwarzwald HL, Mason EO. Staphylococcus aureus Infections in HIV-positive Children and Adolescents. Pediatr Infect Dis J. 2012 Mar. 31(3):284-6. [Medline].

  335. Melles DC, Tenover FC, Kuehnert MJ, Witsenboer H, Peeters JK, Verbrugh HA, et al. Overlapping population structures of nasal isolates of Staphylococcus aureus from healthy Dutch and American individuals. J Clin Microbiol. 2008 Jan. 46(1):235-41. [Medline]. [Full Text].

  336. Mertz PM, Cardenas TC, Snyder RV, Kinney MA, Davis SC, Plano LR. Staphylococcus aureus virulence factors associated with infected skin lesions: influence on the local immune response. Arch Dermatol. 2007 Oct. 143(10):1259-63. [Medline].

  337. Miller CE, Batra R, Cooper BS, Patel AK, Klein J, Otter JA, et al. An Association Between Bacterial Genotype Combined With a High-Vancomycin Minimum Inhibitory Concentration and Risk of Endocarditis in Methicillin-Resistant Staphylococcus aureus Bloodstream Infection. Clin Infect Dis. 2012 Mar. 54(5):591-600. [Medline]. [Full Text].

  338. Miller LG, Eells SJ, Taylor AR, David MZ, Ortiz N, Zychowski D, et al. Staphylococcus aureus Colonization Among Household Contacts of Patients With Skin Infections: Risk Factors, Strain Discordance, and Complex Ecology. Clin Infect Dis. 2012 Jun. 54(11):1523-35. [Medline]. [Full Text].

  339. Miller MB, Weber DJ, Goodrich JS, Popowitch EB, Poe MD, Nyugen V. Prevalence and risk factor analysis for methicillin-resistant Staphylococcus aureus nasal colonization in children attending child care centers. J Clin Microbiol. 2011 Mar. 49(3):1041-7. [Medline].

  340. Milstone AM, Carroll KC, Ross T, Shangraw KA, Perl TM. Community-associated methicillin-resistant Staphylococcus aureus strains in pediatric intensive care unit. Emerg Infect Dis. 2010 Apr. 16(4):647-55. [Medline].

  341. Mishra RP, Mariotti P, Fiaschi L, Nosari S, Maccari S, Liberatori S. Staphylococcus aureus FhuD2 is involved in the early phase of staphylococcal dissemination and generates protective immunity in mice. J Infect Dis. 2012 Oct 1. 206(7):1041-9. [Medline].

  342. Moellering RC, Jr. Why has methicillin-resistant Staphylococcus aureus become such a successful pathogen in adults?. Infect Dis Clin Pract. September 2010. 18(5):292-7.

  343. Mollema FP, Richardus JH, Behrendt M, Vaessen N, Lodder W, Hendriks W. Transmission of methicillin-resistant Staphylococcus aureus to household contacts. J Clin Microbiol. 2010 Jan. 48(1):202-7. [Medline].

  344. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006 Aug 17. 355(7):666-74. [Medline].

  345. Moumile K, Cadilhac C, Lina G. Severe osteoarticular infection associated with Panton-Valentine leukocidin-producing Staphylococcus aureus. Diagn Microbiol Infect Dis. 2006 Sep. 56(1):95-7. [Medline].

  346. Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P. Early Use of Daptomycin Versus Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia With Vancomycin Minimum Inhibitory Concentration >1 mg/L: A Matched Cohort Study. Clin Infect Dis. 2013 Jun. 56(11):1562-9. [Medline].

  347. Murray PR, Baron EJ, Pfaller FC. Micrococci and Staphylococci. In: Murray PR, Baron EJ, Pfaller MA, Tenover TC, Yolken RH, eds. Manual of Clinical Microbiology. 7th ed. ASM Press. 264-272.

  348. Naseri I, Jerris RC, Sobol SE. Nationwide trends in pediatric Staphylococcus aureus head and neck infections. Arch Otolaryngol Head Neck Surg. 2009 Jan. 135(1):14-6. [Medline].

  349. Nathwani D, Tillotson GS. Vancomycin for Staphylococcus aureus therapy of respiratory tract infections: the end of an era?. Int J Antimicrob Agents. 2003 Jun. 21(6):521-4. [Medline].

  350. Nguyen HH. Hospitalist to home: outpatient parenteral antimicrobial therapy at an academic center. Clin Infect Dis. 2010 Sep 15. 51 Suppl 2:S220-3. [Medline].

  351. Nienaber JJ, Sharma Kuinkel BK, Clarke-Pearson M, Lamlertthon S, Park L, Rude TH. Methicillin-Susceptible Staphylococcus aureus Endocarditis Isolates Are Associated With Clonal Complex 30 Genotype and a Distinct Repertoire of Enterotoxins and Adhesins. J Infect Dis. 2011 Sep. 204(5):704-713. [Medline].

  352. Noah MA, Dawrant M, Faulkner GM, et al. Panton-Valentine leukocidin expressing Staphylococcus aureus pneumonia managed with extracorporeal membrane oxygenation: experience and outcome. Crit Care Med. 2010 Nov. 38(11):2250-3. [Medline].

  353. Noskin GA, Rubin RJ, Schentag JJ, et al. National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998-2003). Clin Infect Dis. 2007 Nov 1. 45(9):1132-40. [Medline].

  354. O'Hara FP, Guex N, Word JM, Miller LA, Becker JA, Walsh SL. A Geographic Variant of the Staphylococcus aureus Panton-Valentine Leukocidin Toxin and the Origin of Community-Associated Methicillin-Resistant S. aureus USA300. J Infect Dis. 2008 Jan 15. 197(2):187-194. [Medline].

  355. Odell CA. Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) skin infections. Curr Opin Pediatr. 2010 Jun. 22(3):273-7. [Medline].

  356. Orendi JM, Coetzee N, Ellington MJ, et al. Community and nosocomial transmission of Panton-Valentine leucocidin-positive community-associated meticillin-resistant Staphylococcus aureus: implications for healthcare. J Hosp Infect. 2010 Aug. 75(4):258-64. [Medline].

  357. Orscheln RC, Hunstad DA, Fritz SA, et al. Contribution of genetically restricted, methicillin-susceptible strains to the ongoing epidemic of community-acquired Staphylococcus aureus infections. Clin Infect Dis. 2009 Aug 15. 49(4):536-42. [Medline].

  358. Otter JA, Yezli S, French GL. The role played by contaminated surfaces in the transmission of nosocomial pathogens. Infect Control Hosp Epidemiol. 2011 Jul. 32(7):687-99. [Medline].

  359. Paladino JA, Poretz D. Outpatient parenteral antimicrobial therapy today. Clin Infect Dis. 2010 Sep 15. 51 Suppl 2:S198-208. [Medline].

  360. Park JY, Jin JS, Kang HY, et al. A comparison of adult and pediatric methicillin-resistant Staphylococcus aureus isolates collected from patients at a university hospital in Korea. J Microbiol. 2007 Oct. 45(5):447-52. [Medline].

  361. Pastacaldi C, Lewis P, Howarth P. Staphylococci and staphylococcal superantigens in asthma and rhinitis: a systematic review and meta-analysis. Allergy. 2011 Apr. 66(4):549-55. [Medline].

  362. Pimentel JD, Meier FA, Samuel LP. Chorioamnionitis and Neonatal Sepsis from Community-associated MRSA. Emerg Infect Dis. 2009 Dec. 15(12):2069-71. [Medline].

  363. Powers ME, Kim HK, Wang Y, Bubeck Wardenburg J. ADAM10 mediates vascular injury induced by Staphylococcus aureus a-hemolysin. J Infect Dis. 2012 Aug 1. 206(3):352-6. [Medline].

  364. Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008 Feb 15. 46(4):584-93. [Medline].

  365. Rasigade JP, Laurent F, Lina G, et al. Global distribution and evolution of Panton-Valentine leukocidin-positive methicillin-susceptible Staphylococcus aureus, 1981-2007. J Infect Dis. 2010 May 15. 201(10):1589-97. [Medline].

  366. Rathore MH. The unique issues of outpatient parenteral antimicrobial therapy in children and adolescents. Clin Infect Dis. 2010 Sep 15. 51 Suppl 2:S209-15. [Medline].

  367. Redwood M, McCabe R. Four cases of community-associated methicillin-resistant Staphylococcus aureus pericarditis. Infect Dis Clin Pract. July 2010. 18(4):251-2.

  368. Reed C, Kallen AJ, Patton M, Arnold KE, Farley MM, Hageman J. Infection With Community-Onset Staphylococcus aureus and Influenza Virus in Hospitalized Children. Pediatr Infect Dis J. 2009 Jul. 28(7):572-576. [Medline].

  369. Rehm SJ, Tice A. Staphylococcus aureus: methicillin-susceptible S. aureus to methicillin-resistant S. aureus and vancomycin-resistant S. aureus. Clin Infect Dis. 2010 Sep 15. 51 Suppl 2:S176-82. [Medline].

  370. Rim JY, Bacon AE 3rd. Prevalence of community-acquired methicillin-resistant Staphylococcus aureus colonization in a random sample of healthy individuals. Infect Control Hosp Epidemiol. 2007 Sep. 28(9):1044-6. [Medline].

  371. Rochon-Edouard S, Pestel-Caron M, Lemeland JF, Caron F. In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother. 2000 Nov. 44(11):3055-60. [Medline]. [Full Text].

  372. Rojo P, Barrios M, Palacios A, Gomez C, Chaves F. Community-associated Staphylococcus aureus infections in children. Expert Rev Anti Infect Ther. 2010 May. 8(5):541-54. [Medline].

  373. Rose WE, Eickhoff JC, Shukla SK, Pantrangi M, Rooijakkers S, Cosgrove SE. Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia. J Infect Dis. 2012 Nov 15. 206(10):1604-11. [Medline].

  374. Ross Nolet B. Update and overview of outpatient parenteral antimicrobial therapy regulations and reimbursement. Clin Infect Dis. 2010 Sep 15. 51 Suppl 2:S216-9. [Medline].

  375. Rossini CJ, Moriarty KP, Tashjian DB, Garb JL, Wait RB. Geographic distribution of community-acquired methicillin-resistant Staphylococcus aureus soft tissue infections. J Pediatr Surg. 2011 Jun. 46(6):1089-92. [Medline].

  376. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008 Jun 1. 46 Suppl 5:S378-85. [Medline].

  377. Ruebner R, Keren R, Coffin S, Chu J, Horn D, Zaoutis TE. Complications of central venous catheters used for the treatment of acute hematogenous osteomyelitis. Pediatrics. 2006 Apr. 117(4):1210-5. [Medline].

  378. Saavedra-Lozano J, Mejias A, Ahmad N, et al. Changing trends in acute osteomyelitis in children: impact of methicillin-resistant Staphylococcus aureus infections. J Pediatr Orthop. 2008 Jul-Aug. 28(5):569-75. [Medline].

  379. Sahu DN, Thomson S, Salam A, Morton G, Hodgkins P. Neonatal methicillin resistant Staphylococcus aureus conjunctivitis. Br J Ophthalmol. 2006 Jun. 90(6):794-5. [Medline].

  380. Sakoulas G, Golan Y, Lamp KC, Friedrich LV, Russo R. Daptomycin in the treatment of bacteremia. Am J Med. 2007 Oct. 120(10 Suppl 1):S21-7. [Medline].

  381. Salerno D, Vahid B, Marik PE. Methicillin-resistant Staphylococcus aureus pneumonia after thoracic surgery: successful treatment with linezolid after failed vancomycin therapy. Ann Thorac Surg. 2007 May. 83(5):1888-91. [Medline].

  382. Schlievert PM. Cytolysins, Superantigens, and Pneumonia Due to Community-Associated Methicillin-Resistant Staphylococcus aureus. J Infect Dis. 2009 Sep 1. 200(5):676-8. [Medline].

  383. Seybold U, Halvosa JS, White N, Voris V, Ray SM, Blumberg HM. Emergence of and risk factors for methicillin-resistant Staphylococcus aureus of community origin in intensive care nurseries. Pediatrics. 2008 Nov. 122(5):1039-46. [Medline].

  384. Shane AL, Hansen NI, Stoll BJ, Bell EF, Sánchez PJ, Shankaran S, et al. Methicillin-Resistant and Susceptible Staphylococcus aureus Bacteremia and Meningitis in Preterm Infants. Pediatrics. 2012 Mar 12. [Medline].

  385. Shilo N, Quach C. Pulmonary infections and community associated methicillin resistant Staphylococcus aureus: a dangerous mix?. Paediatr Respir Rev. 2011 Sep. 12(3):182-9. [Medline].

  386. Skurnik D, Kropec A, Roux D, Theilacker C, Huebner J, Pier GB. Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy. Clin Infect Dis. 2012 Nov. 55(9):1188-97. [Medline]. [Full Text].

  387. Stacey DH, Fox BC, Poore SO, Bentz ML, Gutowski KA. Community-acquired methicillin-resistant staphylococcus aureus: diagnosis and treatment update for plastic surgeons. Plast Reconstr Surg. 2008 Oct. 122(4):120e-7e. [Medline].

  388. Stevens AM, Hennessy T, Baggett HC, Bruden D, Parks D, Klejka J. Methicillin-Resistant Staphylococcus aureus carriage and risk factors for skin infections, Southwestern Alaska, USA. Emerg Infect Dis. 2010 May. 16(5):797-803. [Medline].

  389. Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis. 2006 Jan 1. 42 Suppl 1:S51-7. [Medline].

  390. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis. 2007 Jan 15. 195(2):202-11. [Medline].

  391. Tacconelli E, Cataldo MA. Antimicrobial therapy of Staphylococcus aureus bloodstream infection. Expert Opin Pharmacother. 2007 Oct. 8(15):2505-18. [Medline].

  392. Tacconelli E, De Angelis G, de Waure C, Cataldo MA, La Torre G, Cauda R. Rapid screening tests for meticillin-resistant Staphylococcus aureus at hospital admission: systematic review and meta-analysis. Lancet Infect Dis. 2009 Sep. 9(9):546-54. [Medline].

  393. Tattevin P, Diep BA, Jula M, Perdreau-Remington F. Methicillin-resistant Staphylococcus aureus USA300 clone in long-term care facility. Emerg Infect Dis. 2009 Jun. 15(6):953-5. [Medline].

  394. Tattevin P, Schwartz BS, Graber CJ, Volinski J, Bhukhen A, Bhukhen A, et al. Concurrent epidemics of skin and soft tissue infection and bloodstream infection due to community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2012 Sep. 55(6):781-8. [Medline].

  395. Thomsen I, McKenna BD, Saye EJ, Jimenez N, Edwards KM, Creech CB. Molecular distinctions exist between community-associated methicillin-resistant Staphylococcus aureus colonization and disease-associated isolates in children. Pediatr Infect Dis J. 2011 May. 30(5):418-21. [Medline]. [Full Text].

  396. Tice AD, Rehm SJ. Meeting the challenges of methicillin-resistant Staphylococcus aureus with outpatient parenteral antimicrobial therapy. Clin Infect Dis. 2010 Sep 15. 51 Suppl 2:S171-5. [Medline].

  397. Tolan RW Jr. Toxic shock syndrome complicating influenza A in a child: case report and review. Clin Infect Dis. 1993 Jul. 17(1):43-5. [Medline].

  398. Tolan RW Jr. Community-associated methicillin-resistant Staphylococcus aureus: overview of our current understanding. US Infectious Disease 2007. November 2007. II:52-4. [Full Text].

  399. Tong SY, Lilliebridge RA, Bishop EJ, et al. Clinical correlates of Panton-Valentine leukocidin (PVL), PVL isoforms, and clonal complex in the Staphylococcus aureus population of Northern Australia. J Infect Dis. 2010 Sep 1. 202(5):760-9. [Medline].

  400. Top KA, Buet A, Whittier S, Ratner AJ, Saiman L. Predictors of Staphylococcus aureus rectovaginal colonization in pregnant women and risk for maternal and neonatal infections. J Pediatr Infect Dis Soc. April 2012. 1(1):7-15.

  401. Top KA, Huard RC, Fox Z, Wu F, Whittier S, Della-Latta P, et al. Trends in methicillin-resistant Staphylococcus aureus anovaginal colonization in pregnant women in 2005 versus 2009. J Clin Microbiol. 2010 Oct. 48(10):3675-80. [Medline]. [Full Text].

  402. Torres A. Antibiotic Treatment Against Methicillin-Resistant Staphylococcus aureus Hospital- and Ventilator-acquired Pneumonia: A Step Forward but the Battle Continues. Clin Infect Dis. 2012 Mar. 54(5):630-2. [Medline].

  403. Van De Griend P, Herwaldt LA, Alvis B, DeMartino M, Heilmann K, Doern G. Community-associated methicillin-resistant Staphylococcus aureus, Iowa, USA. Emerg Infect Dis. 2009 Oct. 15(10):1582-9. [Medline].

  404. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of Mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev. 2012 Apr. 25(2):362-86. [Medline].

  405. Velissariou IM. Linezolid in children: recent patents and advances. Recent Patents Anti-Infect Drug Disc. 2007 Jan. 2(1):73-7. [Medline].

  406. Viallon A, Marjollet O, Berthelot P, et al. Risk factors associated with methicillin-resistant Staphylococcus aureus infection in patients admitted to the ED. Am J Emerg Med. 2007 Oct. 25(8):880-6. [Medline].

  407. Villaruz AE, Wardenburg JB, Khan BA, et al. A Point Mutation in the agr Locus rather than Expression of the Panton-Valentine Leukocidin Caused Previously Reported Phenotypes in Staphylococcus aureus Pneumonia and Gene Regulation. J Infect Dis. 2009 Sep 1. 200(5):724-734. [Medline]. [Full Text].

  408. Wald ER. Staphylococcus aureus: Is It a Pathogen of Acute Bacterial Sinusitis in Children and Adults?. Clin Infect Dis. 2012 Mar. 54(6):826-31. [Medline].

  409. Wang JT, Liao CH, Fang CT, Chie WC, Lai MS, Lauderdale TL, et al. Incidence of and risk factors for community-associated methicillin-resistant Staphylococcus aureus acquired infection or colonization in intensive-care-unit patients. J Clin Microbiol. 2010 Dec. 48(12):4439-44. [Medline]. [Full Text].

  410. Waters AE, Contente-Cuomo T, Buchhagen J, Liu CM, Watson L, Pearce K. Multidrug-Resistant Staphylococcus aureus in US Meat and Poultry. Clin Infect Dis. 2011 May. 52(10):1227-30. [Medline].

  411. Wendt C, Schinke S, Wurttemberger M, et al. Value of whole-body washing with chlorhexidine for the eradication of methicillin-resistant Staphylococcus aureus: a randomized, placebo-controlled, double-blind clinical trial. Infect Control Hosp Epidemiol. 2007 Sep. 28(9):1036-43. [Medline].

  412. Wenzel RP. Minimizing surgical-site infections. N Engl J Med. 2010 Jan 7. 362(1):75-7. [Medline].

  413. West SK, Plantenga MS, Strausbaugh LJ,. Use of decolonization to prevent staphylococcal infections in various healthcare settings: results of an Emerging Infections Network survey. Infect Control Hosp Epidemiol. 2007 Sep. 28(9):1111-3. [Medline].

  414. Wieland BW, Marcantoni JR, Bommarito KM, Warren DK, Marschall J. A Retrospective Comparison of Ceftriaxone Versus Oxacillin for Osteoarticular Infections Due to Methicillin-Susceptible Staphylococcus aureus. Clin Infect Dis. 2012 Mar. 54(5):585-90. [Medline].

  415. Wilson AP, Hayman S, Whitehouse T, et al. Importance of the environment for patient acquisition of methicillin-resistant Staphylococcus aureus in the intensive care unit: a baseline study. Crit Care Med. 2007 Oct. 35(10):2275-9. [Medline].

  416. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003 Nov. 124(5):1789-97. [Medline].

  417. Yao D, Yu FY, Qin ZQ, et al. Molecular characterization of Staphylococcus aureus isolates causing skin and soft tissue infections (SSTIs). BMC Infect Dis. 2010 May 26. 10:133. [Medline]. [Full Text].

  418. Zaoutis TE, Toltzis P, Chu J, et al. Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among children with risk factors for health care-associated infection: 2001-2003. Pediatr Infect Dis J. 2006 Apr. 25(4):343-8. [Medline].

  419. Zhang K, McClure JA, Elsayed S, Tan J, Conly JM. Coexistence of Panton-Valentine Leukocidin-Positive and -Negative Community-Associated Methicillin-Resistant Staphylococcus aureus USA400 Sibling Strains in a Large Canadian Health-Care Region. J Infect Dis. 2008 Jan 15. 197(2):195-204. [Medline].

  420. Zingg W, Posfay-Barbe KM, Pittet D. Healthcare-associated infections in neonates. Curr Opin Infect Dis. 2008 Jun. 21(3):228-34. [Medline].

Previous
Next
 
Posteroanterior chest radiograph of a 15-year-old with staphylococcal endocarditis and multiple septic emboli, revealing borderline cardiomegaly, multiple nodular infiltrates, and bilateral pleural effusions.
Lateral chest radiograph of a 15-year-old with staphylococcal endocarditis and multiple septic emboli, revealing borderline cardiomegaly, multiple nodular infiltrates, and bilateral pleural effusions.
CT scan of the thorax (mediastinal windows) of a 15-year-old with staphylococcal endocarditis and multiple septic emboli, revealing bilateral pleural effusions.
CT scan of the thorax (lung windows) of a 15-year-old with staphylococcal endocarditis and multiple septic emboli, demonstrating multiple nodular infiltrates (some with cavitation) consistent with septic emboli, volume loss on the right, and pleural effusions.
CT scan of the thorax (lung windows) of a 15-year-old with staphylococcal endocarditis and multiple septic emboli, revealing multiple nodular infiltrates (some with cavitation) consistent with septic emboli, volume loss on the right, and pleural effusions.
CT scan of the thorax (lung windows) of a 15-year-old with staphylococcal endocarditis and multiple septic emboli, revealing multiple nodular infiltrates (some with cavitation) consistent with septic emboli, volume loss on the right, and pleural effusions.
CT scan of the thorax (lung windows) of a 15-year-old with staphylococcal endocarditis and multiple septic emboli, revealing multiple nodular infiltrates (some with cavitation) consistent with septic emboli, volume loss on the right, and pleural effusions.
Follow-up CT scan of the thorax (lung windows) of a 15-year-old with staphylococcal endocarditis and multiple septic emboli, revealing multiple nodular infiltrates (some with cavitation) consistent with septic emboli, volume loss on the right, and pleural effusions.
Follow-up CT scan of the thorax (lung windows) of a 15-year-old with staphylococcal endocarditis and multiple septic emboli, revealing multiple nodular infiltrates (some with cavitation) consistent with septic emboli and evolution of the lesions over time.
Follow-up CT scan of the thorax (lung windows) of a 15-year-old with staphylococcal endocarditis and multiple septic emboli, revealing multiple nodular infiltrates (some with cavitation) consistent with septic emboli and evolution of the lesions over time.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.